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A NOVEL COGNITIVE STRESS TEST FOR THE DETECTION OF EARLY
ALZHEIMER’S DISEASE IN AFRICAN AMERICANS
by
Kimberly Estelle Capp M.A., M.S.
Nova Southeastern University
ABSTRACT
The U.S. population is currently undergoing a major demographic transition, with
increasing racial and ethnic diversity of the older adult population. As the growing
population of older adults advances in age, memory complaints are projected to increase
in prevalence particularly among African Americans and present a challenge to clinicians
who must differentiate between normal aging and progressive neurocognitive conditions
(Celsis, 2000; Sherwin, 2000). As targeted therapeutic interventions and emerging
therapies for AD are much more likely to be effective in the earlier stages of the disease
(Loewenstein, Curiel, Duara & Buschke, 2017), early assessment and detection of AD,
especially in groups more likely to develop the disorder, such as African Americans, has
become increasingly important. As such, the current study examined the performance of
African Americans, both cognitively normal and those with amnestic-mild cognitive
impairment (aMCI), on a novel cognitive stress test, the Loewenstein-Acevedo Scale of
Semantic Interference and Learning (LASSI-L) and found that those with aMCI exhibit
more impairment in their initial learning and storage of information and suffer from
proactive semantic interference due to their inability to inhibit responses. Additionally,
this study found that the LASSI-L serves as a better predictor of diagnostic group
classification compared to traditional neuropsychological measures. Taken together these
findings suggest that the LASSI-L is a highly promising test for the assessment of mild

cognitive impairment among African American older adults, which will hopefully guide
prevention and treatment planning within this underserved population.

Chapter 1: Introduction
The U.S. population is currently undergoing a major demographic transition, with
increasing racial and ethnic diversity of the older adult population. Over the next several
decades one in every five Americans will be age 65 or older and by 2050, the proportion
of minorities will far outnumber non-Hispanic whites (U.S. Census Bureau, 2017). As the
growing population of older adults advances in age, memory complaints are projected to
increase in prevalence and present a challenge to clinicians who must differentiate
between normal aging and progressive neurocognitive conditions, such as Alzheimer’s
disease (Celsis, 2000; Sherwin, 2000). Alzheimer’s disease (AD), the most prevalent
neurocognitive disorder, is highest among African Americans who are 64% more likely
to develop AD when compared to Caucasians (Steenland, Goldstein, Levey, & Wharton,
2016). Despite this higher prevalence, AD in African Americans has gone largely
understudied. Increased understanding of AD in African Americans, specifically
regarding measures that effectively provide early detections can provide important
insights regarding the characteristics of observed memory deficits as well as which of
characteristics is more predictive of AD brain pathology and further progression to full
AD. Given the paucity of research in the area, this dissertation study examines effective
early detection of Alzheimer’s disease in African Americans.
Alzheimer’s Disease
Alzheimer’s Disease (AD) is a progressive degenerative disease of the brain,
beginning in middle age or later life, which is characterized by progressive cognitive
decline and brain pathology (Logie, Parra, & Della Sala, 2015; Saykin and Rabin, 2014).
While several neuropathological these changes occur in AD, research has primarily
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focused on the presence of the deposition of amyloid-beta (A ) peptide (plaques) and
intraneuronal fibrils composed of abnormal tau proteins (tangles) (Hyman et al., 2012).
The typical presentation of AD includes an insidious onset, memory impairment, and a
gradually progressive course evolving to include declines in other cognitive functions as
well as personality, emotion, and functional abilities (Saykin & Rabin, 2014). Currently,
a diagnosis of Alzheimer’s dementia is based on meeting the criteria outlined in the
following three classification systems: 1) Diagnostic Statistical Manual of Mental
Disorders, 5th edition (DSM-5; refer to Appendix A), 2) the International Classification
of Diseases, 10th edition (ICD-10; refer to Appendix B), or 3) the National Institute of
Neurological and Communicative Disorders and Stroke (NINCDS) of the United States
and the Alzheimer’s Disease and Related Disorders Association (ADRDA) (NINCDSADRDA; refer to Appendix C).
AD was first described in 1906 by German psychiatrist and neuropathologist,
Alois Alzheimer (Zilka & Novak, 2006; Cipriani, Dociotti, Picchi, & Conuccelli, 2011).
Dr. Alzheimer, whose initial work largely focused on correlating psychiatric symptoms to
pathology of the nervous system, examined a woman by the name of Auguste Deter who
was suffering from memory loss, disorientation, depression, and hallucinations (Zilka &
Novak, 2006; Cipriani, Dociotti, Picchi, & Conuccelli, 2011). After her death at age 55,
Dr. Alzheimer examined Auguste’s brain using the newly developed Bielschowsky’s
silver staining method and described what he saw: “in the center of an otherwise almost
normal cell, there stands out one or several fibrils due to their characteristic thickness and
peculiar impregnability. Numerous small military foci are found in the superior layers.
They are determined by the storage of a peculiar substance in the cerebral cortex. All in
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all, we have to face a peculiar disease” (as cited by Cipriani, Dociotti, Picchi, &
Conuccelli, 2011, p. 277; Alzheimer, 1907). These observations made by Dr. Alzheimer
would be later recognized today as the plaques and tangles characteristic in the brains of
patients with the disease. Dr. Alzheimer continued to study patients similar to Auguste
and the disease was later termed “Alzheimer’s disease” by Dr. Emil Kraepelin,
Alzheimer’s mentor, in the 8th edition of his Handbook of Psychiatry (Cipriani, Dociotti,
Picchi, & Conuccelli, 2011; Kraepelin, 1910).
Research investigating AD has continued in the hundred years since it was first
described by Dr. Alzheimer. Today two variants of AD are recognized: sporadic and
familial (Schoenberg & Duff, 2011). Sporadic AD, which accounts for over 95% of
cases, develops after the age of 65 and follows a slow and insidious course which lasts
roughly 10 years (Saykin & Rabin, 2014; Schoenberg & Duff, 2011). Sporadic AD is
associated with the APOE gene, of which there are three alleles: epsilon 2, 3, and 4
(Saykin and Rabin, 2014). Because over 60% of AD patients are homozygous for APOE
ε4, this allele is considered a risk factor for the development of AD (Saykin & Rabin,
2014). The familial variant of AD occurs before the age of 65 and follows a more rapid
progression (Schoenberg & Duff, 2011). The familial variant is associated with mutations
in three genes (APP, PSEN1, PSEN2) resulting in autosomal dominant AD by
upregulating the production of amyloid beta protein (Saykin & Rabin, 2014). While other
genome studies have investigated additional genes associated with AD, none has proven
to be useful in predicting the development of AD (Saykin & Rabin, 2014).
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The AD Continuum
Historically, AD was synonymous with the later dementing stage of disease,
however recent technological advances have allowed us to examine more closely the
changes in the brain that occur early in the disease (Sperling et al., 2011). Over the last
decade, research has demonstrated that biological changes characteristic of AD (i.e.
plaques and tangles) can be detected through cerebral spinal fluid (CSF) and imaging (i.e.
MRI and PET amyloid scans) decades prior to the stage of dementia (Sperling, Mormino,
& Johnson, 2014). As a result, AD is now conceptualized as a continuum, ranging from
individuals at risk for further decline (i.e. evidencing biological correlates of AD) to the
later dementing stage of the disease (Dubois et al., 2016). Based on these biological
correlates (i.e. plaques and tangles), researchers have determined that AD occurs in three
phases: the preclinical stage, mild cognitive impairment (MCI), and dementia (Sperling et
al., 2011). Although exact transitional periods are difficult to determine, and likely
involve some overlap (Sperling et al., 2011), understanding the different phases of AD is
important in that it allows for the diagnostic accuracy of patient presentation as well as
the identification of potentially optimal opportunities to employ treatments and emerging
therapies. In order to provide clarity, the following sections will review the three stages
of AD.
Preclinical AD. The preclinical stage of AD represents a new addition to the AD
disease model (Dubois et al., 2016). Individuals identified as being in the preclinical
stage are those who evidence biomarkers which are signature of the disease, namely A
and tau depositions, but whose cognitive functioning is normal on objective
neuropsychological measures (Duara et al., 2011). These neuropathological changes
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serve as biomarkers for the identification of the disease and can be identified by
laboratory tests such as Positron Emission Tomography (PET) amyloid imaging or by
assessing the ratios of A and tau present in cerebrospinal fluid (CSF) (Loewenstein et
al., 2012). Other biomarkers used include the identification of medial temporal atrophy
on magnetic resonance imaging (MRI), regional hypometabolism on PET scans,
abnormal functional MRI activation patterns, and the presence of an Apolipoprotein 4
genotype (Loewenstein et al., 2012; Sperling et al., 2011).
As previously mentioned, individuals in the preclinical stage of AD evidence
normal cognitive functioning on objective neuropsychological measures. Despite this,
these individuals often report subjective cognitive decline (SCD) or “perceived decline in
memory and/or other cognitive abilities relative to their previous level of performance, in
the absence of objective neuropsychological deficits” (Rabin, Smart, & Amariglio, 2017;
Jessen et al., 2014). Several studies have demonstrated the association between SCD and
the accumulation of A , finding that increased reports of subjective memory concerns are
associated with increased A and neuritic plaque burden (Sperling, Mormino, & Johnson,
2014; Rabin, Smart, & Amariglio, 2017; Amariglio et al., 2012; Perrotin et al., 2012;
Harten et al., 2013; Kryscio et al., 2014). These findings suggest that SCD may be an
indicator of preclinical AD and that individuals with SCD may be at increased risk for
future pathological decline (Rabin, Smart, & Amariglio, 2017).
Multiple longitudinal studies have demonstrated high progression rates of
preclinical AD to later stages of the disease. These studies have consistently
demonstrated that individuals who evidence increased A deposits are more likely to
experience accelerated cognitive decline compared to those without (Wirth et al., 2013;
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Mormino et al., 2014; Lim et al., 2014; Landau et al., 2012). While individuals with
abnormal biomarkers do not always progress to MCI, studies have found that progression
rates are highest in those with subjective memory difficulties not significant enough to
warrant a diagnosis of MCI (38.9%) and those with A and an additional biomarker such
as elevated tau (32.7%) (Vos et al., 2013; Loewenstein et al., 2012). Of note, research on
preclinical AD progression rates has largely failed to examine racial disparities,
particularly in African Americans. As a result, little is known about how progression
rates in African Americans may compare to those of other racial groups. A thorough
literature review only identified one study conducted by Chen et al. (2017) examining the
progression from normal cognition to mild cognitive impairment (MCI) in a diverse
sample. This study investigated progression rates among Whites (N= 92), African
Americans (N=78), and Hispanics (N= 84) from both clinic (N=13) and community (N=
241) samples over a 7-year period. Results from this study found progression rates for
clinic samples to be 30% per year, whereas the conversion rate for the community sample
was 5% per year (Chen et al., 2017). Hispanics had the highest progression rates with no
significant difference observed between the progression rates of Whites and African
Americans (Chen et al., 2017). Consistent with previous research, older age and SCD
were risk factors for progressing from normal cognition to MCI (Chen et al., 2017).
While this study examined racial differences in progression rates from normal cognition
to MCI, more research is needed to examine factors that may influence progression rates
in racially and ethnically diverse populations.
Mild Cognitive Impairment. Individuals who progress from a normal level of
cognition enter an intermediate phase of clinically probable AD. This intermediate phase
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has been termed “mild cognitive impairment” (MCI) (Albert et al., 2011; Petersen, 2004)
and represents the stage of cognitive impairment seen between those with normal
cognition and those with dementia (Petersen et al., 1999). In 2011, the National Institute
on Aging- Alzheimer’s Association (NIA-AA) developed core clinical criteria for the
diagnosis of MCI to be utilized by healthcare providers without access to advanced
imaging techniques or cerebrospinal fluid analysis (Albert et al., 2011). According to
these criteria a diagnosis of MCI is made when there is a) concern regarding a change in
cognition b) impairment in one or more cognitive domains c) preservation of
independence in functional abilities and d) no evidence of dementia (Albert et al., 2011).
In order to make a diagnosis of MCI there first should “be evidence of concern
about a change in cognition, in comparison with the person’s previous level” (Albert et
al., 2011, p.271). This concern regarding a change in cognition “can be obtained from the
patient, from an informant who knows the patient well, or from a skilled clinician
observing the patient” (Albert et al., 2011, p. 271). Once it has been established that there
is concern regarding a change in cognition, formal cognitive testing should be conducted
to determine if there is impairment in one or more cognitive domains (i.e. memory,
executive functioning, attention, language, and visuospatial skills1) (Albert et al., 2011).
Individuals with memory impairment, more specifically in episodic memory (i.e. the
ability to learn and retain new information) most commonly progress from MCI to AD
dementia (Albert et al., 2011). Impairment is characterized as “lower performance in one
or more cognitive domains that is greater than would be expected for the patient’s age

1

For more information regarding cognitive domains interested readers are referred to
Diagnostic and statistical manual of mental disorders (5th ed., pp.593-595).
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and educational background” which is demonstrated by test scores 1 to 1.5 standard
deviations below what would be expected for age and education matched peers (Albert et
al., 2011, p. 271). If the patient is tested repeatedly, a decline in performance should be
evident over time (Albert et al., 2011).
If it has been determined than an individual has impairment in one or more
cognitive domains, their level of independence and functional abilities should be assessed
to establish that functioning is not so severely impaired that a diagnosis of dementia is
warranted (Albert et al., 2011). Those with MCI should demonstrate a preservation of
independence in functional abilities such as preparing meals, paying bills, and shopping
(Albert et al., 2011). While patients may demonstrate mild problems completing these
tasks (i.e., taking more time to complete a task, being less efficient, making more errors)
they should be able to complete these tasks with minimal aids or assistance (Albert et al.,
2011). Lastly, it is important to note that those with MCI should not meet criteria for
dementia as “these cognitive changes should be sufficiently mild that there is no evidence
of a significant impairment in social or occupational functioning” (Albert et al., 2011, p.
272).
Individuals in the MCI phase of AD are considered at risk for further decline to
AD dementia (Petersen, 2011). Longitudinal studies have shown that the rate of
conversion from MCI to dementia over a three-year period ranges from 20% to 53%
(Black, 1999; Mckelvey et al., 1999; Wolf et al., 1998) and 100% conversion to AD
dementia is seen during a 9.5-year period (Morris et al., 2001). Progression rates for
African Americans are largely understudied as the vast majority of research includes
exclusively Caucasian participants or fails to separately report progression rate estimates
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by racial group (Gao et al., 2014). However, a recent study investigating MCI
progression in African Americans found an annual progression rate of 5.9%, which is
comparable to rates found in Caucasian samples (Gao et al., 2014). While progression
rates are largely understudied in diverse populations, research suggests that the greatest
risk factors for progressing to AD dementia is the presence of memory deficits and
multiple AD biomarkers (Vos et al., 2013; Loewenstein et al., 2012).
AD Dementia. During the last stage of AD, individuals progress to a state of
dementia which is a “clinical syndrome characterized by a loss of previously acquired
cognitive functions that adversely affects an individual’s ability to complete day to day
activities” (Schoenberg & Duff, 2011, p.357). According to the NIA-AA, the diagnosis
of AD dementia is made when there are cognitive or behavioral symptoms that: a)
interfere with the ability to function at work or at usual activities; b) represent a decline
from previous levels of functioning and performing; and c) are not explained by delirium
or major psychiatric disorder (McKhann et al., 2011). Cognitive impairment due to
dementia can be “detected and diagnosed through a combination of (1) history taking
from the patient and a knowledgeable informant and (2) an objective cognitive
assessment, either a “bedside” mental status examination or neuropsychological testing”
(McKhann et al., 2011, p. 265). This cognitive impairment involves a minimum of two of
the following domains (i.e. memory, reasoning or judgement, visuospatial abilities,
language functions, changes in personality or behavior) (McKhann et al., 2011). AD
dementia involves an insidious onset with symptoms gradually presenting over months to
years (McKhann et al., 2011). As mentioned previously, those with AD dementia
evidence cognitive impairment in numerous domains. For those with AD dementia, the
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initial and most prominent cognitive deficits follow either an Amnestic or Nonamnestic
presentation (McKhann et al., 2011). The Amnestic presentation of AD dementia is the
most common and includes impairments in learning and recall of newly learning
information (McKhann et al., 2011). While memory is the primary deficit, those with an
Amnestic presentation must also evidence deficits in at least one other cognitive domain
such as attention, executive functioning, visuospatial functioning, or language (McKhann
et al., 2011). Nonamnestic presentations of AD dementia are less common and involve
primary deficits in language, visuospatial, or executive functioning2 as opposed to
memory (McKhann et al., 2011).
Prevalence studies indicate that the rate of AD dementia in the U.S. is estimated
to be least 4.7 million (Herbert, Weuve, Scherr, & Evans, 2013; Alzheimer’s Association,
2017). Furthermore, studies indicate that the risk of developing AD seems to be highest
among African Americans who are 64% more likely to develop AD when compared to
Caucasian Americans (Steenland, Goldstein, Levey & Wharton, 2016). Several studies
have examined the incidence and prevalence of AD dementia by race (Hebert et al., 2010;
Tang et al., 2001; Katz et al., 2012; Kukull et al., 2002; Fitzpatrick et al., 2004;
Plassmann et al., 2011) including a meta-analysis conducted by Steenland et al. (2016),
which found that the estimated AD prevalence rates for those ages 65-90 years to be
5.5% for Whites and 8.6% for African Americans. Similar results were observed in a
review conducted by Mehta and Yeo (2017) who examined the prevalence and incidence
rates of all types of dementia diagnosis among different racial and ethnic groups and

2

Expanded information regarding AD deficits in language, visuospatial and executive
functioning can be found below in the Neurocognitive Symptoms of AD section.
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found higher dementia prevalence rates for African Americans, ranging from 7.2% to
20.9%, with an average annual incidence rate of 2.6%. Taken together, the higher
incidence and prevalence of AD dementia rates in African Americans likely reflects a
combination of biological, psychological, and socioeconomic factors.
Symptoms of AD
Given that AD is the most prevalent of the dementia syndromes, identifying
contributing signs and symptoms of the disease has become increasingly important.
Research has identified several neuropathological signs, neuropsychological symptoms,
and neurocognitive symptoms characteristic of AD (Schoenberg & Duff, 2011).
Neuropathology of AD. Since AD was first described by Dr. Alois Alzheimer in
1906, research has continued to investigate the neuropathology of the disease (Zilka &
Novak, 2006; Cipriani, Dociotti, Picchi, & Conuccelli, 2011). Definitive diagnosis of AD
can only be made at autopsy because the brain of an individual with AD does not show
any gross anatomical alterations that can be identified diagnostically. Thus, a histological
examination must be conducted to observe microscopic evidence of the disease (Perl,
2010). There are three pathognomonic changes which can be detected in the brain of
someone with AD: amyloid-beta (A ) peptide deposits or “plaques”, neurofibrillary
“tangles” composed of tau proteins, and brain atrophy (Raskin, Cummings, Hardy,
Schuh, & Dean, 2015). Other changes that occur include “synaptic loss, neuronal loss,
gliosis, degenerative changes in white matter, granulovacuolar degeneration, cerebral
amyloid angiopathy, and other protein aggregates” (Raskin, Cummings, Hardy, Schuh, &
Dean, 2015).
Currently, the amyloid hypothesis is the dominant model of AD neuropathology
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and is based on the discovery that the amyloid precursor protein (APP) gene on
chromosome 21 leads to the development of typical Alzheimer neuropathology secondary
to the production of too much A (Selkoe & Hardy, 2016). According to this hypothesis,
changes in A metabolism, which may result from genetic mutations, results in a relative
increase in A (Raskin, Cummings, Hardy, Schuh, & Dean, 2015). This increase in A
results in the formation of plaques, which results in changes in synaptic function and
local inflammatory responses (Raskin, Cummings, Hardy, Schuh, & Dean, 2015). This
inflammation results in synaptic loss, neuritic dystrophy and over time oxidative stress
along with altered neuronal ionic homeostasis and other biochemical changes (Raskin,
Cummings, Hardy, Schuh, & Dean, 2015). Following these events, tau protein is
hyperphosphorylated leading to intraneuronal neurofibrillary tangles (Raskin, Cummings,
Hardy, Schuh, & Dean, 2015). This cascade results in widespread synaptic and neuronal
dysfunction, as well as, cell death which then leads to extensive A and tau pathology
resulting in progressive dementia (Raskin, Cummings, Hardy, Schuh, & Dean, 2015).
In short, the progression of AD is typically characterized by buildup of amyloid
plaques followed by the development of neurofibrillary tangles. In the early stages of
AD, early accumulation of abnormal brain amyloid can be detected in several brain areas
(e.g., precuneus, posterior cingulate, anterior cingulate and frontal, temporal, parietal
cortical regions). These amyloid deposits, which can be indicators of early fibrillary
formation in cognitively intact individuals, are detectable 20 years or more before the
emergence of any significant neuropsychological deficits (Loewenstein et al., 2017).
Neurofibrillary tangles, which emerge later in the disease course, have been found to
appear in the pyramidal cells of the neocortex, hippocampus, amygdala, and brainstem
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(Zec, 1993). Because AD damage often occurs first in the temporal lobe and associated
structures, deficits in memory and higher-order cognitive functioning are typically
noticed early on (Salmon & Bondi, 2009; Zec, 1993). As the disease progresses other
brain areas are affected (e.g. prefrontal and parietal), with motor and sensory cortical
areas usually remaining intact (Perl, 2010).
Neuropsychiatric Symptoms of AD. Neuropsychiatric symptoms (NPS), defined
as noncognitive behavioral and psychiatric symptoms including disturbances of mood,
perception, and behavior, are also associated with neurodegenerative diseases (Ismail et
al., 2016). NPS, which are common in MCI and dementia, have been associated with
poorer outcomes, increased caregiver burden, increased functional impairment, higher
rates of institutionalization, poorer quality of life, higher burden of neuropathological
markers of dementia, and accelerated progression to severe dementia or death (Ismail et
al., 2016; Lyketsos et al., 2011; Fischer, Ismail, & Schweizer, 2012; Balestreri,
Grossberg, & Grossberg, 2000; Karttunen et al., 2011; Peters et al., 2015; Zubenko et al.,
1991). Several studies have identified four different types of NPS: hyperactivity (i.e.,
aggression, disinhibition, irritability, aberrant motor behavior and euphoria), psychosis
(i.e., delusion, hallucination and sleep disorder), affective (i.e., depression and anxiety)
and apathy (i.e., apathy and appetite disorder) (Zhao et al., 2016; Aalten et al., 2007;
Cheng et al., 2012). Studies investigating the prevalence rates of NPS have offered mixed
results, likely due to differences in study settings, population demographics, evaluation
methods, and severity of cognitive impairment (Zhao et al., 2016; Fuh, 2006; Mega et al.,
1996; Teri et al., 1988). In an effort to produce more precise estimates of NPS prevalence
in AD, Zhao et al. (2016) conducted a meta-analysis and found that the most frequently
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reported NPS in those with AD was apathy 49%, followed by depression 42%,
aggression 40%, anxiety 39%, and sleep disorder 39%. Because NPS commonly occurs
in neurodegenerative disease such as AD and other dementias, early recognition and
intervention may aid in improving the prognosis of the patient (Zhao et al., 2016).
Neurocognitive Symptoms of AD. Due to pathological changes in the brain,
which interrupt neural networks, individuals with AD evidence several cognitive deficits.
In fact, deficits in episodic memory, or the ability to learn and retain new information, is
considered the clinical hallmark of AD (Weintraub, Wicklund, & Salmon, 2012).
Research indicates that deficits in episodic memory stem from an individual’s inability to
properly consolidate and store new information (Broe et al., 2003). What little
information is consolidated is quickly forgotten and there is rarely an improvement over
the amount of information an individual can learn across numerous trials (Weintraub,
Wicklund, & Salmon, 2012). As a result, on measures of immediate and delayed
memory, individuals with AD evidence impaired performance, with delayed memory
typically being most impaired (Harciarek & Jodzio, 2005). When given tasks involving
recognition memory where individuals are given memory cues, individuals with AD
evidence impaired performance often producing both false positive (i.e., endorsing a
stimulus as being present when it was not) and false negative errors (i.e., rejecting a
stimulus when it was present) (Weintraub, Wicklund, & Salmon, 2012).
In addition to memory impairment, individuals with AD may also present with
deficits in other cognitive domains such as language, visuospatial, or executive
functioning. In those with deficits in language functioning, the individual experiences
difficulty with word-finding, confrontation naming (i.e. the ability to name a viewed
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stimulus, verbal comprehension, and semantic verbal fluency (i.e. categories) (McKhann
et al., 2011;Harciarek & Jodzio, 2005;Weintraub, Wicklund, & Salmon, 2012;
Rascovsky, Salmon, Hansen, Thal, & Galasko, 2007).
The deficits in visuospatial functioning in those with AD include impaired spatial
cognition (i.e. knowledge about environment), object agnosia (i.e. inability to recognize
objects), impaired face recognition, simultanagnosia (i.e. inability to perceive more than
one object at a time), alexia (i.e. inability to read), and constructional apraxia (i.e.
inability to build, assemble, or draw objects) (Parasuraman, Greenwood, & Alexander,
2000; Thompson, Stopford, Snowden, & Neary, 2005; McKhann et al., 2011).
Deficits in executive functioning include impaired attention (e.g. divided
attention), reasoning, decision making, judgment (e.g. poor understanding of safety
risks), and problem solving (e.g. difficulty planning complex or sequential activities)
(McKhann et al., 2011; Perry & Hodges, 1999).
Even with these deficit areas, global deficits in AD are not typically manifested
until the later stages of the disease when individuals increasingly are affected by agnosia
(i.e. inability to interpret sensory information), apraxia (i.e. inability to perform
purposeful motor actions), and aphasia (i.e. loss of ability to understand or express
speech) (Schoenberg & Scott, 2011).
AD in African Americans
Research investigating knowledge and beliefs about AD between racial groups
indicates that African Americans have more racial constrained beliefs about the disease
(Dilworth-Anderson, Gibson, & Burket, 2013; Jett, 2006; Mahoney et al., 2005). For
example, studies indicate that at the initial stages of memory loss, family members report
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difficulty distinguishing memory loss from personality or normal aging (i.e. viewing their
older relative as just “slipping”) (Dilworth-Anderson, Gibson, & Burket, 2013; Jett,
2006). When family members observe memory loss, it is often attributed to other health
conditions (e.g. diabetes, neurosyphilis) or emotional distress (e.g. depression, stress)
(Potter, Roberto, Brossoie, & Blieszner) rather than a dementing illness. Moreover,
family members often times report being unsure at which point memory loss becomes
severe enough to indicate dementia (Potter, Roberto, Brossoie, & Blieszner, 2017; Cahill,
Pierce, Werner, Darley, & Bobersky, 2015). Additionally, research shows that African
Americans are significantly more likely than Caucasian Americans to perceive memory
loss and dementia as a normal part of aging and are thus more likely to accept changes
rather than viewing them as problematic (Mahoney, Cloutterbuck, Neary, & Zhan, 2005;
Potter et al., 2017). While some studies attribute these “misconceptions” regarding AD
symptoms to disparities in education, income, and access to information among African
Americans, research controlling for these variables still find these racial constrained
beliefs prevalent among African Americans (Dilworth-Anderson & Gibson, 2002; Lee et
al., 2012; Connell et al., 2009; Mahoney et al., 2005).
Research demonstrates that in the instances where memory loss is viewed as
problematic, affected individuals and their family members are more likely to seek help
from other family members, friends, or trusted allies such as the church rather than health
care providers due to historic discrimination, intergenerational traumatization and current
experiences of discrimination (Mahoney et al., 2005; Dilworth-Anderson, Gibson, &
Burket, 2013; Jett, 2006). Mistrust in healthcare providers and the health care system
amongst African Americans is often attributed to “the unique combination of racism,
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slavery and segregation”3 which has been exacerbated by historical ethical violations,
such as the Tuskegee syphilis experiment (Kennedy, Mathis, & Woods, 2007, p. 57.;
Boulware, Cooper, Ratner, LaVeist, & Powe, 2003). In fact, study conducted by Green
and colleagues (1997) found that Fifty-two percent of African Americans were aware of
the Tuskegee Study and that Twenty-two percent of these individuals reported that
because of the study they would be less likely to participate in research themselves.
Exacerbating these factors and reinforcing this narrative are continued concerns about
interpersonal and technical competence of health care providers, as well as, expectations
of racism and experimentation during routine health care (Jacobs, Rolle, Ferrans,
Whitaker, & Warnecke, 2006). Unfortunately these expectations of discrimination, are
often reinforced by microaggressions (i.e. “brief and commonplace daily verbal,
behavioral, or environmental indignities, whether intention or unintentional, that
communicate hostile, derogatory, or negative racial slights”) (Sue, Capodilupo, Torino,
Bucceri, Holder, Nadal, & Esquilin, 2007) such as African Americans having memory
concerns dismissed and memory problems attributed to drinking habits (Boulware, et al.,
2003; Mahoney et al., 2005). Furthermore, given the institutionalized racism embedded
within the United States physicians perceive African Americans more negatively on a
number of barriers that affect health care (Van Ryn, & Burke, 200), and African
Americans, particularly those who endorse high perceptions of racism and classism,
report less satisfaction with health care as well as less treatment adherence (Glover, Sims,
& Winters, 2017, Cuffee, Hargraves, Rosal, Briesacher, Schoenthaler, Person,... &

3

Interested readers are directed to Kennedy and colleagues (2007) review African
Americans and Their Distrust of the Health Care System: Healthcare for Diverse
Populations.
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Allison, 2013; Sims, Diez-Roux, Gebreab, Brenner, Dubbert, Wyatt,... & Taylor, 2016;
Hausmann, Hannon, Kresevic, Hanusa, Kwoh, & Ibrahim, 2011). Given that majority of
African Americans relate their experiences of discrimination to race/ethnicity, and
roughly two thirds of graduating physicians are Caucasian, it is not surprising that
African Americans report more discrimination and distrust in physicians than any other
racial or ethnic group (Banks, Kohn-Wood,& Spencer, 2006; Mickelson &Williams,
1999; Castillo-Page, 2010; Hausmann, et al., 2011; Sims, et al., 2016; Cuffee, et al.,
2013; Jacobs, et al., Glover, et al., 2017). As a result of these factors, conducting medical
and psychological research within the African American community, including that on
AD, faces a number of barriers which unfortunately adversely affect the research body
(Hamel, Penner, Albrecht, Heath, Gwede, & Eggly, 2016). This is particularly
problematic as the rate of AD in African Americans is higher than that of other group and
projected to increase as the baby boomers enter late life (Mehta & Yeo, 2017; Colby &
Ortman, 2017).
Risk and Protective Factors. Given that the rate of AD in African Americans is
higher than that of other groups, and a projected increase in this population expected over
the next few decades, understanding factors that protect or contribute to AD in African
Americans has become increasingly important (Colby & Ortman, 2017). Research
examining the higher incidence rates of AD in African Americans points to several risk
factors, including those in the biological, health, and psychological domains.
Biological Risk Factors. One of the most established biological risk factors for
AD is the prevalence of an Apolipoprotein 4 (APOE 4) genotype (Schoenberg & Scott,
2011). While rates of this genotype has been found to be higher in African Americans
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than in Whites, research has failed to demonstrate a consistent relationship between
APOE 4 prevalence, AD, and cognitive decline in African Americans (Barnes &
Bennett, 2014; Logue et al., 2011; Evans et al., 2003; Reitz et al., 2013). A likely reason
for the inconsistency among research findings to date rests in the fact that, for research
described above, African Americans are generally underrepresented in AD research, most
of which involves non-Hispanic Whites (Shin, & Doraiswamy, 2016). Recently, one of
the largest genome studies involving African Americans was conducted and confirmed
that the APOE 4 allele, along with the ABCA7 gene, is related to increased risk of
Alzheimer’s disease among African Americans (Reitz et al., 2013).
Health Risk Factors. A number of health conditions more prevalent in the
African American population such as diabetes, hypertension, and obesity have been
identified as capable of increasing the risk of developing AD (Barnes & Bennett, 2014;
Steenland et al., 2016). These health risk conditions occur more often in African
American populations compared to Whites and are likely the result of environmental,
biological, and socioeconomic factors (Barnes & Bennett, 2014; Steenland et al., 2016).
Specifically, African Americans are at least 50% more likely to have diabetes than
Whites (Signorello et al., 2007; Carter & Pugh, 1996; Centers for Disease Control and
Prevention, 2003; Mokdad et al., 2003; Harris et al., 1998; Cowie, Harris, Silverman,
Johnson, & Rust, 1993; & Harris et al., 1990), 51% more likely to be obese (Center for
Disease Control and Prevention, 2009), and 13% more likely to have hypertension then
their White peers (Murray et al., 2018; Nwankwo, Yoon, Burt, & Gu, 2013). One
explanation for this link may be that dementia in African Americans is most often of
mixed pathology, often involving vascular factors which increase risk of further cognitive
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decline (Barnes & Bennett, 2014; Steenland et al., 2016). However, more data is needed
to investigate the relationship between these conditions and the neuropathology present in
AD, particularly in the African American population.
Psychological Risk Factors. While psychological factors have been shown to
increase the risk associated with cognitive decline and progression to AD, few studies to
date have examined these factors in African Americans. For example, both depression
and chronic stress have been linked to higher rates of AD and since African Americans
report higher incidence of depression and stress, these psychological factors may play a
larger role in AD for this population (Turner, Capuano, Wilson & Barnes, 2015;
Machado et al., 2014; Zannas et al., 2015). Social issues such as racial discrimination
have also been linked to decreased psychological well-being and higher rates of
depression and stress in African Americans, as well as, health care satisfaction and
treatment adherence (Hudson, Neighbors, Geronimus, & Jackson, 2015; Glover, Sims, &
Winters, 2017; Sims, et al., 2016). As such, more studies are needed to examine
psychological and sociological factors that negatively impact African Americans and the
extent to which these factors further contribute the higher incidence of AD seen in this
population.
Protective Factors. In addition to the aforementioned risk factors, a number of
protective factors have been identified within African American communities focused on
spirituality, religious involvement and family support. Churches have long been viewed
as trusted organizations within African American communities, and as a result, many
African American families report relying on their churches for support and as a source of
information during times of need (Taylor, Chatters, Woodward, & Brown, 2013;
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Mahoney et al., 2005). Similarly, African American families report a preference to rely
on trusted and understanding family members and close friends for help rather than
seeking outside help, with some individuals’ insisting on complete reliance on family due
to views of familial responsibility (Potter, et al., 2017).
Studies demonstrate that religious and spiritual involvement along with strong
family support serves as a protective lifestyle factor for individuals experiencing
cognitive decline (Agli Bailly, & Ferrand, 2014). Religious attendance and social
activities (i.e. singing, praying, attending sermons, studying scripture, socializing) have
been found to benefit cognitive health by promoting active and engaging lifestyles which
require various cognitive exercises (Hill, 2008; Agli et al., 2014; McNamara, 2002).
These cognitive exercises strengthen frontal circuits in the brain, train episodic memory,
improve introspection and attention which may prevent or delay cognitive decline (Hill,
2008; Agli et al., 2014; McNamara, 2002; Koenig, 2012). Further, religious and social
involvement provide outlets for psychological stressors, reduce anxiety, reduce
depression, and provide a greater sense of meaning and life purpose (Hill, 2008).
Reduced psychological stress protects against elevated blood cortisol levels which may
otherwise result in hippocampal atrophy and subsequent memory loss (Hill, 2008;
Conrad, 2008; Csernansky et al., 2006; Sapolsky, 2000).
For those diagnosed with AD, personal faith, prayer, church connections, and
family support enabled individuals to keep a positive attitude as they came to terms with
living with the disease (Agli et al., 2014). Further, individuals who put their lives in the
hands of a third party, namely God, reportedly feel more confident and secure, felt
relieved from worrying about an uncertain future, and adapted better their diagnosis
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(Stuckey, 2003; Beuscher & Grando, 2009). African Americans providing care to a
family member diagnosed with AD are also likely to benefit from religious involvement
and additional family support. Research has shown that African American caregivers
exhibit higher levels of religiosity compared to their Caucasian counterparts as a response
to caregiving strains (Dilworth-Anderson, Williams, Gibson, 2002; Wykle & Segall,
1991) and that this religiosity along with additional family support lead to less caregiver
burden and stress and more positive appraisals of caregiving (Wilks, Spurlock, Brown,
Teegen, & Geiger, 2018; Napoles et al., 2010).
AD Diagnostic Methods
Traditionally, AD is diagnosed during the later stages of the disease when there is
evidence of impairment in memory and at least one additional cognitive domain other
than memory, which interfere with activities of daily living (Dubois et al., 2007). While
corroborating biomarker evidence may indicate brain pathology early in AD, imaging and
laboratory assessments are both costly and offer limited diagnostic clarity since known
biomarkers have also been found across a broad clinical spectrum including cognitively
normal individuals (McKhann et al., 2011). Thus, in order to gain diagnostic clarity,
individuals are often referred for a neuropsychological evaluation to assess cognitive
functioning. Because deficits in memory, and more specifically episodic memory, are the
hallmark feature of AD, the evaluation of memory performance is essential to determine
if AD related impairments are present.
Traditional neuropsychological measures used to assess memory disorders were
originally developed to identify advanced memory impairments seen in dementia and are
based on paradigms that have gone relatively unchanged for over 60 years (Brooks &
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Loewenstein, 2010). Several studies have found that these traditional measures lack the
sensitivity needed to detect earlier stages of AD, as cognitive changes occurring during
this period are more subtle (Rentz et al, 2013; Pettigrew et al., 2015). In fact, research has
demonstrated that individuals in the preclinical stage of AD, who evidence abnormal
amyloid and tau deposition, score in the normal range on these traditional measures
(Rentz et al, 2013; Pettigrew et al., 2015). Because neuropathological changes are present
up to 20 years or more before observable deficits are present, those individuals at risk of
further decline may go undetected by traditional measures. Efforts to mitigate this issue
have examined the sensitivity of composite scores comprised of several traditional
measures used together; however, it has been shown that his method is also insensitive to
subtle changes in memory (Loewenstein et al., 2017).
In addition to their lack of sensitivity, traditional measures also fail to account for
realistic environmental challenges and individual differences (Loewenstein et al., 2017).
Specifically, the administration of traditional measures occurs under optimal conditions
including a quiet environment and minimized distractions. Unfortunately, this pristine
testing environment does not translate well to the demands in the real-world environment
in which people are required to use multiple cognitive resources, multitask, and manage a
wide array of stimuli simultaneously (Loewenstein et al., 2017). As such individuals in
optimal testing environments are not required to utilize as many cognitive resources and
therefore typically perform better than they would in the real-world. This is due to the
fact that these optimal environments allow individuals to employ cognitive reserve and
compensatory strategies that may mask underlying neuropsychological deficits (Stern,
2009).
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In regard to individual differences, traditional measures have largely
underrepresented minority individuals in their normative samples. Previous normative
studies have included only a small number of African American participants with diverse
ages and educational levels and have generally not excluded participants with neurologic
disease or those who develop dementia after a short follow up (Schneider et al., 2015;
Lucas et al., 2005; Dotson, Kitner-Triolo, Evans, & Zonderman, 2008; Holtzer et al.,
2008). In addition to insufficient normative data, research has demonstrated racial
disparities in testing performance. Research has found that African Americans, along
with other minority groups, typically score lower than Whites on traditional measures of
verbal and nonverbal abilities despite equivalent education and socioeconomic level
which further reduces specificity of cognitive impairment (Schneider et al., 2015;
Mayeux et al., 2011; Snitz et al., 2009; Cerhan et al., 1998). While these studies have
utilized covariance or matching procedures to equate racial groups based on years of
education prior to examining test performance, other studies argue that matching based
on years of education likely does not address performance discrepancies between racial
groups as the quality of education may not be comparable (Manly et al., 1998; Kaufman
et al., 1997; Loewenstein et al., 1994; Whitfield & Baker-Thomas, 1999). Research has
demonstrated that African Americans have reading skills significantly below their selfreported education levels (Albert & Teresi, 1999; Baker et al., 1996). This discrepancy is
likely due in part to the history of segregation of schools in the United States (Manly et
al., 1998). Many older African Americans attended segregated schools which received
inferior funding, had lower quality teachers, had higher ratios of students to teachers, and
lacked sufficient teaching resources (Hanushek, 1989; Hedges et al., 1994; O’Neill,
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1990). In addition, African American children were often employed, which reduced their
school attendance during the year (Margo, 1985). To address this issue, researchers have
adjusted for quality of education as measured by reading ability rather than years of
education and have found that the effect of race on test performance was no longer
significant (Manly et al, 2002).
Traditional Memory Paradigms. Traditional memory paradigms are based on
the notion that rapid rate of forgetting and impaired delayed recall is one of the most
sensitive indicators of AD and can best predict progression to dementia in cognitively
normal individuals (Loewenstein et al., 2004; Ashford et al., 1989; Locasio et al., 1995;
Troster et al., 1993; Welsh et al., 1991; Masur et al., 1994). More recently, it has been
recognized that deficits in initial learning may play a larger role demonstrating that
attentional resources and learning strategies may impact memory processes (Greenaway
et al., 2006; Schneider, Boyle, Arvanitakis, Bienias & Bennet, 2007; Loewenstein et al.,
2017; Loewenstein et al., 2003). One of the most common memory paradigms utilized to
assess both traditional and more recent indicators of AD, is list learning, which includes
the presentation of stimuli to be remembered over several learning trials. These
assessments examine different aspects of memory such as storage and consolidation,
immediate and delayed memory, and recognition of target stimuli (Loewenstein, Curiel,
Duara, & Buschke, 2017). Neuropsychological assessments based on this traditional
memory paradigm include the Rey Auditory Verbal Learning Test (Schmidt, 1996), the
Hopkins Verbal Learning Test-Revised (Brandt & Benedict, 2001), the Buschke
Selective Reminding Test (Buschke & Fuld, 1974), the California Verbal Learning TestSecond Edition (Delis, Kramer, Kaplan, & Ober, 2000) and the Consortium to Establish a
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Registry for Alzheimer’s Disease List-Learning Test (Morris et al., 1989). Other
commonly used traditional memory paradigms include the examination of immediate and
delayed memory for story passages as seen on the Wechsler Memory Scale Fourth
Edition (WMS-IV) Logical Memory subtest, paired associate learning as seen on the
WMS-IV Verbal Paired Associates subtest, and retention of simple or complex geometric
designs as seen on the Brief Visual Memory Test-Revised (BVMT-R) and the Rey
Complex Figure Test (RCFT) (Wechsler, 2009; Benedict, 1997; Meyers & Myers, 1995;
Loewenstein, Curiel, Duara, & Buschke, 2017).
While traditional memory paradigms rely on passive encoding through the
presentation of stimuli to-be-remembered over several learning trials, newer paradigms
have employed an active encoding approach. These more active paradigms, termed
controlled learning paradigms, avoid the limitations of traditional list learning measures
by providing the examinee with a cue that the to-be-remembered information should be
organized by, and by doing so, increase the depth of processing and encoding of the
information presented (Loewenstein et al., 2017; Buschke, Sliwinski, Kuslansky, &
Lipton, 1995; Buschke, Sliwinski, Kuslansky, & Lipton; 1997; Thomson & Tulving,
1970). Not only does controlled learning ensure proper processing and encoding but the
cues used may allow individuals to access information during retrieval (Loewenstein,
Curiel, Duara, & Buschke, 2018). Studies have shown that individuals with AD are
unable to properly use these category cues and thus will still demonstrate impaired
performance (Adam et al., 2007; Grober & Buschke, 1987; Grober Buschke, Crystal,
Bang, & Dresner, 1988).
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In addition, individuals with AD have been found to be susceptible to semantic
interference, or the ability to deal with competing stimuli within a semantic category, on
a number of measures (Loewenstein et al., 2003; Loewenstein et al., 2004; Ebert &
Anderson, 2009; Cushman et al., 1988; Davis et al., 2002). Semantic interference can be
further differentiated into proactive and retroactive semantic interference. Proactive
semantic interference (PSI) occurs when old semantic learning interferes with the
learning of new semantic information (Loewenstein et al., 2017). This is demonstrated by
list learning measures in which the learning of a first semantic category (Animals)
repeated over multiple trials interferes with the learning of the same semantic category on
a second list. For example, if a person is unable to recall a newly presented word to-beremembered such as “Dog” because they previously learned and remember the word
“Cat,” proactive interference has occurred. Retroactive semantic interference (RSI)
occurs when newly learned semantic information interferes with previously learned
semantic information (Loewenstein et al., 2017). RSI is demonstrated by list learning
measures when the recall of the first category of semantic stimuli (Animals) is difficult
due to interference of the second list of semantic stimuli. For example, if a person is
unable to recall the word “Tiger” because more recently they were given the word “Lion”
to remember, retroactive interference has occurred.
While traditional memory paradigms have examined PSI and RSI, they have
several limitations that reduce their sensitivity to identifying the earliest stages of AD
(i.e. preclinical AD and MCI) (Crocco, Curiel, Acevedo, Czaja, & Loewenstein, 2014).
While some traditional measures may include competing to-be-remembered lists,
controlled learning is not emphasized and there are insufficient numbers of semantically
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to-be-remembered stimuli which does not allow for the appropriate examination of PSI
and RSI (Loewenstein, et al., 2017). Uncontrolled learning in these paradigms thus does
not account for individual attentional resources or learning strategies (Loewenstein et al.,
2018). Furthermore, traditional measures lack multiple trials of the second semantically
related list which prevents the examination of an individual’s ability to recover from
proactive semantic interference (Loewenstein et al., 2017). Recovery from PSI is
valuable in that it represents strong initial learning and memory.
Taken together PSI, RSI, and recovery from PSI enable us to not only compare an
individual to a demographically related normative group, but also to their own initial
learning and retrieval abilities (Loewenstein et al., 2017). Thus, novel measures that
adequately examine controlled learning, PSI, RSI, and recovery from PSI, may
demonstrate enhanced sensitivity to the earlier stages of AD which may also prove
valuable for those racial groups not traditionally represented in normative data.
Novel Memory Paradigm. A novel paradigm, the Loewenstein-Acevedo Scales
of Semantic Interference and Learning (LASSI-L), was developed to address the
aforementioned limitations commonly found in traditional memory paradigms (Curiel et
al., 2013). The LASSI-L instructs a person to remember a list of 15 common words that
are organized around three semantic categories (i.e. fruits, musical instruments, articles of
clothing), with each category consisting of five target words. After reading the list of 15
words, the examinee is asked to recall the words. This free recall is followed by a cued
recall in which the person is presented with each category cue and asked to recall the
words belonging to that category. The person is then presented with the 15 words from
the original list (List A) for a second time and again asked to recall the items belonging to
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each category. Then, a second semantically related list (List B) is presented in the same
manner in which the first list (List A) was administered. Following the presentation of
List B, the person is asked to free recall List B words, assessing for semantic PSI. Free
recall of list B is followed by a cued recall. List B words are presented for a second time,
followed by a second cued recall trial to assess for recovery from PSI. To assess for RSI,
the person is then asked to freely recall the original List A words. This is followed by a
cued recall of List A. After a 20-minute delay the person is asked to freely recall words
from both Lists A and B.
The LASSI-L demonstrates several strengths over traditional memory paradigms
(Loewenstein et al., 2017). First, the LASSI-L explicitly identifies the semantic
categories which learning should be organized before target words are presented. This
explicit identification decreases the impact that attentional resources and learning
strategies may have on memory. Second, the LASSI-L provides a second list of words in
which each word is semantically related to a target on the first list. Third, multiple
exposures to both List A and List B increase encoding by increasing the depth of initial
processing of to-be-remembered information. Lastly, the LASSI-L provides the
evaluation of PSI and RSI as well as a unique measure of recovery from PSI.
LASSI-L Clinical Findings. Validation studies of the LASSI-L have
demonstrated high test-retest reliability as well as high concurrent and discriminant
validity (Loewenstein & Acevedo, 2005; Curiel et al., 2013). Several studies have
demonstrated the LASSI-L’s ability to differentiate between cognitively normal (CN)
individuals and those ranging in severity of impairment (Curiel et al., 2013; Loewenstein
et al., 2016). Diagnostic classification studies with the LASSI-L have found that it
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demonstrated high levels of sensitivity and specificity with an overall correct
classification rate of 90%, which is significantly higher than classification rates obtained
by traditional neuropsychological assessment measures (Curiel et al., 2013; Crocco,
Curiel, Acevedo, Czaja, & Loewenstein, 2014). Similar results were obtained for a
validation study of the LASSI-L among Spaniards (Matias-Guiu et al., 2016). In regard to
severity of impairment, Crocco and colleagues (2014) found that amnestic MCI (aMCI)
patients evidenced higher PSI and RSI effects than CN individuals. These PSI and RSI
effects are due to the LASSI-L’s high degree of shared semantic cueing, which elicits
significant numbers of semantic intrusions, particularly for impaired individuals.
Loewenstein and colleagues (2016) examined the LASSI-L in individuals ranging in
degree of cognitive impairment and found that deficits on the LASSI-L were observed in
89% of those with MCI, 47% of those with preclinical MCI, 33% with subjective
memory complaints, and 13% of those classified as normal.
The LASSI-L has also been shown to correlate with biomarker evidence and brain
structural changes associated with AD. In regard to biomarker evidence, the LASSI-L has
been shown to correlate to amyloid depositions (Loewenstein et al., 2017). Specifically,
deficits on initial learning of List A on the LASSI-L was found to significantly correlate
with amyloid depositions in the anterior cingulate (-.49) and frontal lobes (-.44)
(Loewenstein et al., 2017). When looking at different diagnostic groups (i.e. subjective
memory complaints, preclinical MCI, and MCI), all evidenced deficits in recovery from
PSI which was associated with increased amyloid deposition throughout the entire brain
(rs= -.60), precuneus (rs= -.62), posterior cingulate (rs= -.50), and anterior cingulate (rs=

40

-.48) (Loewenstein et al., 2017). Taken together, these results indicate that the LASSI-L
is sensitive to subtle cognitive impairments and increasing amyloid load.
Studies investigating the LASSI-L and its association to volumetric loss in AD
prone brain areas has found that preclinical MCI individuals evidenced greater LASSI-L
deficits particularly with regards to failure to recover from PSI and delayed recall. These
deficits were associated with increased dilation of the inferior lateral ventricle and
decreased MRI volumes in the hippocampus, precuneus, superior parietal region, and
other AD prone areas (Crocco et al., 2018). Similar results have been observed in
individuals with aMCI. Specifically, aMCI patients who demonstrated failure to recover
from PSI evidenced reduced volumes in the hippocampus (rs=0.49); precuneus (rs =
0.50); rostral middle frontal lobules (rs = 0.54); inferior temporal lobules (rs = 0.49);
superior parietal lobules (rs = 0.47); temporal pole (rs = 0.44); and increased dilatation of
the inferior lateral ventricle (rs = −0.49) (Loewenstein et al., 2017). Taken together these
results demonstrate that performance on the LASSI-L and more specifically observed
frPSI is uniquely and strongly related to volumetric loss in AD prone brain areas.
Clinical Relevance. With the growing number of diverse older adults and rates of
AD expected to increase dramatically over the next few decades, a variety of initiatives
have pushed for an earlier detection of AD in order to provide better treatment (Albert et
al., 2011; Sperling et al., 2011; Dubois et al., 2016). Theoretically, early detection would
allow for earlier treatment or interventions with disease modifying therapies before the
onset of dementia (Dubois et al, 2016). While no such intervention or therapy currently
exists, early interventions may benefit patients by stopping or significantly slowing the
progression of AD or by increasing the time spent in the mild stages of the disease
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(Dubois et al., 2016). An intervention of this ability would dramatically reduce health
care costs. Projections estimate that an intervention that delayed the onset of AD
dementia by 5 years would result in a 57% reduction in the number of patients affected
which would reduce the costs of Medicare from $627 to $344 billion dollars (Sperling et
al., 2011). This delay would also result in prolonged functional independence and greater
quality of life for patients and their families. Patients and their families would then be
able to better plan and prepare for the future by having the opportunity to make living,
care, financial and legal arrangements while they still have preserved insight (Antoine &
Pasquier, 2013; Holt, 2011; Mattsson, Brax, & Zetterberg, 2010; Dubois et al., 2016).
Early detection would also allow those in healthcare to better serve patients.
Physicians would have the opportunity to offer therapies that address symptoms such as
anxiety or impaired sleep while also monitoring prescribed medications that could
inadvertently exacerbate dementia (Dubois et al., 2016). With the clear benefits of early
detection and promise of novel disease modifying pharmacological interventions on the
horizon, it is increasingly important to develop diagnostic tools capable of identifying
AD in the earlier stages.
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Chapter 2: Purpose and Specific Aims
The purpose of this dissertation study is to extend the body of research on
effective early detection of AD in African Americans. While the LASSI-L has
demonstrated effectiveness above and beyond traditional measures at differentiating
between normal individuals and those ranging in severity of impairment, these studies
have largely consisted of White and Hispanic individuals. Therefore, this study will
examine the performance of African Americans, both cognitively normal and those with
amnestic-mild cognitive impairment, on the LASSI-L. Further, this study will assess if
the LASSI-L serves as a better predictor of diagnostic group classification and MRI
volumetric reductions in AD prone areas in African Americans compared to traditional
neuropsychological measures.
This dissertation was designed to fulfill three specific aims, which, along with the
related research questions, are detailed below.
Specific Aim 1: Explore Whether There are Differences in Performance on the LASSIL Between aMCI and Cognitively Normal African American Older Adults.
Research Question 1a. When cognitive status is grouped by amnestic-MCI and
cognitively normal are there statistically significant differences in African American
older adults cognitive status when examined in terms of LASSI-L measures reflecting
initial learning and storage of information?
Research Question 1b. When cognitive status is grouped by amnestic-MCI and
cognitively normal are there statistically significant differences in African American
older adults cognitive status when examined in terms of LASSI-L measures reflecting
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proactive semantic interference (PSI) and failure to recover from proactive semantic
interference (frPSI)?
Research Question 1c. When cognitive status is grouped by amnestic-MCI and
cognitively normal are there statistically significant differences in African American
older adults cognitive status when examined in terms of LASSI-L measures reflecting
retroactive semantic interference (RSI)?
Research Question 1d. When cognitive status is grouped by amnestic-MCI and
cognitively normal are there statistically significant differences in African American
older adults cognitive status when examined in terms of LASSI-L measures reflecting
delayed recall?
Research Question 1e. After controlling for covariates, are there differences on
LASSI-L measures by diagnostic group in African American older adults.
Specific Aim 2: To Determine if Performance on the LASSI-L Serves as a Better
Predator of Diagnostic Group Classification Compared to Other Neuropsychological
Tests in African American Older Adults.
Research Question 2a. What is the relationship between scores obtained on the
LASSI-L and diagnostic group classification in African American Older Adults?
Research Question 2b. What is the relationship between scores on traditional
neuropsychological measures and diagnostic group classification in African American
Older Adults?
Specific Aim 3: To Explore How Neuropsychological Measures are Related to
Volumetric Reductions in AD Prone Regions in African American Older Adults.
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Research Question 3a. Are LASSI-L measures of PSI and frPSI related to MRI
Volumetric Reductions in left hemisphere AD prone regions?
Research Question 3b. Are Traditional Neuropsychological Measures related to
MRI Volumetric Reductions in left hemisphere AD prone regions?
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Chapter 3: Methods
Participants and Procedure
This dissertation study examined 44 (28 male, 16 female) independent community
dwelling African Americans aged 60-years-old or older (mean age=64.5 years, SD=
4.45), with the vast majority having a high school education (mean=12.4; SD=1.66).
Participant data was selected from an NIH-funded study at the University of Miami
School of Medicine, which was designed to measure the longitudinal trajectories of
decline in PreMCI participants. Participants in this NIH-funded study were recruited from
the University of Miami’s Center on Aging/CREATE Center as well as the Memory
Disorder Clinic. Interested individuals were prescreened for eligibility through an
extensive clinical interview, which included the Neuropsychiatric Inventory (NPI), MiniMental State Examination (MMSE) (Folstein et al., 1975), and Clinical Dementia Rating
Scale (CDR) (Morris, 1993). Participants and their informants signed Informed Consent
forms. Eligible participants, who were 60 years of age or older and did not meet DSM-5
criteria for Major Neurocognitive Disorder, active Major Depressive Disorder, active
Substance Use disorder in the last 6 months, or any other neuropsychiatric diagnosis,
were subsequently administered a standard neuropsychological battery. Measures
selected for this study, which are described below, took approximately 45 minutes to
complete and included the Hopkins Verbal Learning Test -Revised (Benedict et al.,
1998), National Alzheimer’s Coordinating Center (NACC) delayed paragraph recall
(Beekly et al., 2007), Category Fluency (Lucas et al., 1998), the Block Design subtest
from the Wechsler Adult Intelligence Scale, Fourth-Edition (Wechsler, 2008), and Trail
Making Test (Parts A and B) (Reitan, 1958). The Loewenstein-Acevedo Scale for
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Semantic Interference and Learning (LASSI-L) was also administered but was not used
for diagnostic determination. Participants received a stipend of fifty dollars for
completing these assessments.
Diagnostic determination was based on the independent clinical interview and
performance on the neuropsychological tests. Participants were diagnosed as cognitively
normal (CN) if: a) there was no subjective memory complaints by the participant and/or
collateral informant; b) no evidence by clinical evaluation or history of memory or other
cognitive decline ; c) Global Clinical Dementia Rating Scale of 0; d) the
neuropsychological battery was deemed normal and generally no measures in the
neuropsychological battery fell 1 standard deviation or more below normal limit relative
to age and education normed data. Participants were diagnosed with Amnestic-MCI
(aMCI) if: a) there was subjective memory complaint by the participant and/or collateral
informant; b) Global Clinical Dementia Rating Scale of 0.5; c) no impairment in social
and/or occupational function; d) neuropsychological testing confirmation of memory
impairment as evidenced by performance at or below 1.5 standard deviations expected
for age and education adjusted normative data on the HVLT-R delayed recall or NACC
delayed paragraph recall.
After completing neuropsychological testing, interested and eligible participants
also received MRI scans (n=29). Participants signed separate informed consent forms for
this portion of the study. MRI scans were performed with the 3T Siemens Trio scanner at
the Applebaum Diagnostic Imaging Center, University of Miami Health System, with
assistance of the staff MRI technologists. Total imaging time for each participant was
estimated to be 45 minutes. Participants received an additional fifty-dollar stipend for
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undergoing MRI scans. Psychometrists scoring the cognitive/neuropsychological and
functional evaluations as well as those individuals providing MRI analyses were blind to
participant diagnosis.
For the purpose of this dissertation all participants self-identifying as African
American on a demographic form were selected. Participants were excluded from the
present study’s dataset if they reported a race or ethnicity other than African American
(e.g. Haitian, Cuban, Hispanic)(n=396) and if they did not complete the full
neuropsychological battery (n=5).
Measures
The following measures will be described below: Neuropsychiatric Inventory
(NPI), Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale (CDR),
Hopkins Verbal Learning Test-Revised (HVLT-R), National Alzheimer’s Coordinating
Center (NACC) Delayed Paragraph Recall, Category Naming Fluency, Wechsler Adult
Intelligence Scale, Fourth-Edition (WAIS-IV) - Block Design subtest, Trail Making Test,
and the Loewenstein-Acevedo Scale for Semantic Interference and Learning (LASSI-L).
Neuropsychiatric Inventory (NPI). The Neuropsychiatry Inventory was
developed to assess a wide range of behavior problems common in individuals with
dementia. Ten distinct behavior domains are assessed: delusions, hallucinations,
dysphoria, anxiety, euphoria, agitation/aggression, apathy, irritability/lability,
disinhibition, and aberrant motor behavior. Scripted questions are asked to an informant,
ideally a daily caregiver, about the individual’s behavior in the past month. Each section
has screening questions; if the behavior has occurred, more detailed questioning assesses
its frequency on a 4-point scale and severity on a 3-point scale. An updated version of
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the tests also assesses for sleep and appetite/eating disorders (Cummings, 1997). This
revision also introduced a 6-point caregiver distress scale which ranges from 0 (no
distress) to 5 (very severe distress), which were added to each domain. The suggested
administration time for the original scale was anywhere from 7 to 10 minutes, although
that number is dependent on the informant and how much information they provide.
The NPI has produced high interrater reliability and internal consistency
(Cummings, Mega, Gray, et al., 1994). Test-retest reliability by a second interviewer
within three weeks was generally adequate, with the lowest correlations for
irritability/lability. Neuropsychological findings suggest that all behavior problems
assessed by the NPI were greater in AD patients compared to age-matched control
subjects, of which, the most common was apathy, which was exhibited by 72% of
patients. The NPI has been used successfully to differentiate the behavioral symptoms of
AD and PD (Aarsland et al., 2001), it has also been used to assess psychiatric symptoms
in many subcortical, neurodegenerative disorders (Litvan, Cummings, & Mega, 1998).
Mini-Mental State Examination (MMSE). The MMSE is a cognitive screener
widely used for dementia (Milne et al., 2008). The test assesses a restricted set of
cognitive functions simply and quickly, as a result the standardized administration only
takes about 5 to 10 minutes. A perfect score on the MMSE is 30 points. Points are
obtained from several domains including: working memory (serial 7s and spelling
“world” backwards); language and praxis (naming, following commands, and
construction); orientation; memory (delayed recall of three items); and attention span
(immediate recall of three items) (Banos & Franklin, 2002).
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MMSE scores decrease with age and increase with education (Tombaugh &
McIntyre, 1992). Less educated individuals tend to make errors on the first serial
subtraction, spelling backwards, repeating phrases, writing, naming the season, and
copying (Jones & Gallo, 2002). Cultural and educational limitations need to be
considered as they may lower scores below the cut-off of no cognitive impairment of 24.
African Americans and Hispanics are more likely than European Americans to have been
erroneously identified as demented (Espino et al., 2001). Test-retest reliability over 24
hours for nondemented psychiatric inpatients was high (r = .89, same examiner; r = .83,
different examiner) (Folstein, Folstein, & McHugh, 1975). Four-week test-retest
reliability for dementia patients was nearly perfect (r = .99) (McCaffrey, Duff, and
Westervelt, 2000). The MMSE is most effective in distinguishing patients with moderate
or severe deficits from control subjects (Tombaugh & McIntyre, 1992). It is not as
effective at differentiating between mildly demented patients from normal subjects
(Knight, 1992).
Clinical Dementia Rating Scale (CDR). The CDR compares AD patients with
healthy controls in six categories of cognitive functioning (i.e. memory, orientation,
judgement and problem solving, community affairs, home and hobbies, and personal
care) (Berg et al., 1988). The instrument is administered via a semi-structured interview
to both the participant and an informant (e.g., relative, caregiver). The score is calculated
algorithmically and given on a 5-point scale of impairment (0 = no impairment, 0.5 =
questionable, 1 = mild, 2 = moderate, 3 = severe) (Morris, 1993). There are several
factors that contribute to the utility of the CDR: 1) the six categories used for rating
dementia severity are directly linked to validated clinical diagnostic criteria (Morris,
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Mckeel, Fulling, Torack, & Berg, 1988); 2) it has high inter-rater reliability for both
physicians (Burke et al., 1988) and nonphysicians (McCulla et al., 1989); and 3) an
expanded and more quantitative version of the scale can be obtained by summing the
ratings in each of the six categories to provide an overall sum score (Berg et al., 1988).
Hopkins Verbal Learning Test -Revised (HVLT-R). The HVLT-R is a list
learning task comprised of 12 words, four in each of three semantic categories for three
learning trials. Following a 20 to 25-minute delay patients are asked to recall as many
words as they are capable of. Immediately after the delayed recall a 24-word yes/no
recognition trial is administered containing all 12 target words plus six semantically
related words and six unrelated ones. Scores include one for each learning trial, a total
acquisition score, a learning measure, delayed free recall, percent retention, and delayed
recognition. Recognition scores are calculated for true positives, false positives, a
discrimination index, and a measure of the recognition trial response bias.
A test-retest interval of one year for middle-aged adults produced a moderate total
recall reliability correlation (r = .49) while delayed recall reliability was significant but
lower (r = .36) (Woods et al, 2005). Several variables (i.e. percent retained, learning,
intrusions, and repetitions) indicated lower reliability. Validity studies demonstrated the
comparability of HVLT-R recall and recognition measures to memory measures form
other tests, particularly verbal memory tests (Lacritz et al., 2001; Shapiro et al., 1999).
Neuropsychologically, patients with AD exhibit a learning deficit on the HVLT-R
(Hogervorst et al., 2002). Further, they are more likely to say “yes” to semantically
related foils on the recognition trial (Hogervorst et al., 2002).
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National Alzheimer’s Coordinating Center (NACC) Delayed Paragraph
Recall. NACC delayed paragraph recall requires the subject to recall a story read aloud
by the examiner, both immediately and after a 20-minute delay. Scoring allows several
acceptable responses for each item recalled. Participants can gain points by paraphrasing,
but a verbatim score can also be obtained from allocating a point for each item recalled
exactly as delivered in the story. The verbatim score was intended to serve as potentially
more sensitive than the paraphrase score in detecting very early memory decline (Craft et
al., 2000). The reliability coefficient of the immediate condition for the normative sample
by age group ranged from adequate to high (.77-.88) while delayed recall was high (.80.90) (WMS-IV Technical Manual, 2008). The test-retest reliability of the paragraph recall
was adequate for both the immediate and delayed conditions (.70-.79) (WMS-IV
Technical Manual, 2008). Delayed paragraph recall is also sensitive to AD. Participants
with AD scored significantly lower than matched controls on the delayed condition, with
this difference producing a large effect size (2.20).
Category Naming Fluency. In this task, individuals are simply asked to name as
many animals, fruits, and vegetables that they can think of, without being given any other
cues or restrictions. Individuals with disorders such as those affecting the temporal lobe
have demonstrated category deficits. Temporally-based disorders such as Alzheimer’s
Disease, demonstrate this deficit, which can be attributed to a breakdown in sematic
knowledge about different categories. Normative data for the Category Naming test is
further stratified by age, sex, and education. Contemporary practitioners favor the use of
normative groups established by Heaton in 2004 (Strauss, Sherman, & Spreen, 2006).
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Additional normative data has also been created for Spanish speakers living in the United
States (Acevedo et al., 2000).
Test-retest correlations tend to be high, usually higher than .70 for semantic
fluency with short (e.g., one week) as well as long (e.g., five years) intervals (Basso et al.,
1999; Ross, 2003; Levine et al., 2004). Practice effects can be observed after short retest
intervals. Wilson et al. (2000) showed that fluency for the same category shows a small
but consistent increase across 20 administrations over a span of four weeks. This increase
was observed in normal participants as well as those who had sustained head injuries.
Validity studies looking at correlations between different semantic category tasks (e.g.,
animals, vegetables) are moderately high (.66-.71; Riva et al., 1999); however, the values
are not satisfactorily high to establish equivalency among forms.
Block Design Subtest from the Wechsler Adult Intelligence Scale, FourthEdition. In Block Design, the individual is presented with red and white blocks: two,
four, or nine, depending on the item they are working on. Each block has two white sides,
two red sides, and two half-red half-white sides with the colors divided along the
diagonal. The participant is required to use the blocks to produce replicas of a model
design presented by the examiner within a given amount of time. Block Design items are
presented in order of increasing difficulty. On the sample item and the first four items,
the model design is presented both as a construction made by the examiner and a design
pictured in the test stimulus book. For the next ten items, the model design is presented
only as a picture in the test booklet. The sample item and items 1 and 2 use two blocks;
items 3 to 10 use four blocks; and items 11 through 14 use nine blocks. The WAIS-IV
has a “basal” starting level at item 5 for examinees aged 16 to 90. If the examinee does
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not obtain a perfect score on either item 5 or 6, the preceding items are administered in
reverse order until the examined obtains a perfect score on two consecutive items.
The technical manual reports split-half reliability coefficients for 13 age groups:
these coefficients are all at or above .80 (PyschoCorp, 2008b). Test retest reliability of
the WAIS-IV Block Design for 298 subjects retested over intervals of eight to 82 days
was .80 overall. Test-retest data show a notable improvement from first testing to second
testing, suggesting a significant practice effect. Neuropsychologically, Block Design is
generally recognized as the best Weschler scale measure of visuospatial organization.
Scores tend to be lower in the presence of any kind of brain impairment, indicating that
test performance is affected by multiple factors. Specifically, for patients with AD, Block
Design scores correctly classified 91% of AD patients (Weintraub, Wicklund, & Salmon,
2012). Block Design has also proven to be a useful predictor of the disease as a relatively
low Block Design score in the early stages, when the diagnosis is still in question, may
herald the onset of the disease (Arnaiz et al., 2001). The test is also one of the most useful
neuropsychological tests for predicting which patients will deteriorate the most rapidly
(Small et al., 1997).
Trail Making Test (Parts A and B). The Trail Making Test measures cognitive
flexibility, sequencing ability, and visual-motor speed. The Trail Making Test (parts A
and B) are a subtest from the Army Individual Test (1944) used as measures of attention,
scanning, visual-motor tracking, divided attention, and set-shifting abilities. Trails A is a
measure of visual scanning and motor speed. In Trails A, the participant is given a page
with a set of numbered circles scatters about the page and is asked to draw a line between
consecutive numbers. Trails B is a more specific measure of executive functioning as it
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requires reasoning ability other higher-order processes (Golden, Espe-Pfeifer, &
Wachsler-Feider, 2000; Kortte, Horner, & Windham, 2002). In Trails B, the participant is
given a sheet with randomly distributed circled numbers and circled letters and asked to
draw a line connecting A-1, B-2, C-3, and so forth in a sequencing pattern. Scores are
based on total time to complete task, and the number of errors made. Cut-off scores were
used in the original interpretation of the test (Reitan & Wolfson, 1985), but contemporary
practitioners favor the sensitive of the use of t-scores based normative groups established
by Heaton in 2004 (Strauss, Sherman, & Spreen, 2006). Test-retest reliability has been
shown to vary depending on age and population studied. A study looking at 384 normal
adults aged between 15 and 83 years who were retested about 11 months after the initial
test session showed adequate reliability for Part A (.79) and high for Part B (.89). Similar
findings were reported by Levine et al. (2004) for mostly Caucasian, well-educated male
subjects (.70 for A and B). Mitrushina and Satz (1991) examined test-retest reliability in
older adults after a 1-year period and found coefficients that were low for part A (.53-.64)
and higher for part B (.67-.72). Interrater reliability has been reported as .94 for Part A
and .90 for Part B (Fals-Stewart, 1991). As for sensitivity, the Trail Making Test is
sensitive to dementing disorders such as AD (Chen et al., 2000); however, the task does
not distinguish adequately among dementing disorders (Barr et al., 1992).
Loewenstein-Acevedo Scale for Semantic Interference and Learning (LASSIL). The LASSI-L instructs a person to remember a list of 15 common words that are
fruits, musical instruments or articles of clothing (five words per category). The person is
asked to read the words for the target list out loud as each is presented individually at 4second intervals. In the unlikely event that the person cannot correctly read the word, the
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word is read by the examiner and the person is asked to repeat the word. After the person
has read all 15 words, they are asked to recall the words. After free recall has ended, they
are presented with each category cue (e.g., clothing) and asked to recall the words that
belonged to that category. Participants are then presented with target stimuli for a second
learning trail with subsequent cued recall to strengthen the acquisition and recall of the
List A targets. The exposure to the semantically related list (i.e., List B) is then conducted
in the same manner as exposure to List A. List B consists of 15 words different from List
A, 5 of which belong to each of the three categories used in List A (i.e., fruits, musical
instruments, articles of clothing).
Following the presentation of the List B words, the person is asked to free recall
the List B words, assessing proactive interference effects. Then, each category cue is
given, and they are asked to recall each of the List B words that belonged to each of the
categories. List B words are presented again, followed by a second category-cued recall
trial. Finally, to assess retroactive interference they are asked to free recall the original
list A words. Free-recall and cued recall scores for List A and List B targets are then
obtained after a 30-minute delay. Primary measures for this project are the second cued
recall score, and first cued recall score for list B. Test-retest reliabilities were high and
the accuracy of classification of aMCI patients versus elderly subjects exceeded 90% (see
Crocco et al., 2013; Curiel et al., 2013).

56

Chapter 4: Results
The main objective of this study was to examine the performance of African
Americans, both cognitively normal and those with amnestic-mild cognitive impairment,
on a novel cognitive stress test, the Loewenstein-Acevedo Scale of Semantic Interference
and Learning (LASSI-L) Each of the study’s three specific aims and their associated
results are presented below:
Specific Aim 1: Explore Whether There are Differences in Performance on the LASSIL Between aMCI and Cognitively Normal African American Older Adults.
Assumption analyses included boxplots of all dependent variables to assess for
outliers, and interpretation of the Shapiro-Wilk’s test to determine normality (as n < 50).
There were no outliers in the data, as assessed by inspection of boxplots. Data was
normally distributed, as assessed by Shapiro-Wilk's test (p > .05). For each dependent
variable there was homogeneity of variances, as assessed by Levene’s test for equality of
variances with the exception of LASSI-L List A Free Recall 1 Intrusions, p= .001;
LASSI-L List A Cued Recall 1 Intrusions, p= .000; LASSI-L List A Cued Recall 2
Intrusions, p=.000; LASSI-L List B Cued Recall 1 intrusions, p= .021. For the instances
in which Levene’s test for equality of variance was violated, a series of non-parametric
Mann Whitney U tests of ranks was performed. Because results were the same for
parametric and nonparametric analysis they were still interpreted.
Research Question 1a. When cognitive status is grouped by amnestic-MCI and
cognitively normal are there statistically significant differences in African American
older adults cognitive status when examined in terms of LASSI-L measures regarding
initial learning and storage of information?
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A one-way analysis of variance (ANOVA) was conducted to evaluate the research
question of whether there were statistically significant differences in African American
older adult cognitive status when examined in terms of LASSI-L measures regarding
initial learning and storage of information. A criterion for significance of p < .05 was
used. When examining initial learning and storage of information, cognitively normal
(CN) individuals were found to recall significantly more words than those with aMCI
(Table 4-1). For instance, on the LASSI-L List A Free Recall 1, CN individuals recalled
significantly more words (M= 8.37) compared to aMCI individuals (M= 6.25), F(1,42)=
8.36, p= .006. Similar results were seen on the LASSI-L List A Cued Recall 1 where CN
individuals recalled significantly more words (M=9.79) compared to aMCI individuals
(M=7.70), F(1,42)= 8.34, p= . 006) and on the LASSI-L List A Cued Recall 2, where CN
individuals recalled significantly more words (M=12.70) compared to aMCI individuals
(M=10.25), F(1,42)= 25.94, p= .000. Furthermore, on the LASSI-L List A Cued Recall 1,
CN individuals made significantly fewer intrusions (M=0.25) compared to aMCI
individuals (M=1.05) F(1,42)= 8.27, p=.006. Similar results were seen on the LASSI-L
List A Cued Recall 2, where CN individuals made significantly fewer intrusions
(M=0.12) compared to aMCI individuals (M=.95) F(1,42)=11.309, p= .002. The number
of intrusions made during the initial free recall on the LASSI-L List A Free Recall 1 did
not significantly differ between CN (M=.17) and aMCI (M=.45) individuals
F(1,42)=8.27, p=.09.
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Table 4-1. ANOVA Summary Table for LASSI-L Initial Learning and Storage
SS

df

MS

F

p

LASSI-L List A Free Recall 1
Between Groups
Within Groups
Total

49.261
247.375
296.636

1
42
43

49.261
5.890

8.364

.006*

LASSI-L List A Cued Recall 1
Between Groups
Within Groups
Total

47.728
240.158
287.886

1
42
43

47.728
5.718

8.347

.006*

LASSI-L List A Cued Recall 2
Between Groups
Within Groups
Total

65.928
106.708
172.636

1
42
43

65.928
2.541

25.949

.000*

LASSI-L List A Free Recall 1
Intrusions
Between Groups
Within Groups
Total

.876
12.283
13.159

1
42
43

.876
.292

2.994

.091

LASSI-L List A Cued Recall 1
Intrusions
Between Groups
Within Groups
Total

6.982
35.450
42.432

1
42
43

6.982
.844

8.272

.006*

7.425
27.575
35.000

1
42
43

7.425
.657

11.309

.002*

LASSI-L List A Cued Recall 2
Intrusions
Between Groups
Within Groups
Total
Table Notes. *p<.05
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Research Question 1b. When cognitive status is grouped by amnestic-MCI and
cognitively normal are there statistically significant differences in African American
older adults cognitive status when examined in terms of LASSI-L measures reflecting
proactive semantic interference (PSI) and failure to recover from proactive semantic
interference (frPSI)?
A one-way analysis of variance was conducted to evaluate the research question
of whether there were statistically significant differences in African American older adult
cognitive status when examined in terms of LASSI-L measures reflecting proactive
semantic interference (PSI) and failure to recover from proactive semantic interference
(frPSI). A criterion for significance of p < .05 was used. On LASSI-L measures reflecting
PSI, (Table 4-2), results demonstrated higher scores for those who were CN compared to
those with aMCI. For instance, on the LASSI-L List B Free Recall those who were CN
freely recalled more words (M= 6.45) than those with aMCI (M= 4.85). This difference
was statistically significant, F(1,42) = 5.85, p= .020. On LASSI-L List B Cued Recall 1
those who were CN recalled more words when cued (M= 7.16) than those with aMCI
(M= 5.00). This difference was statistically significant, F(1,42)= 8.424, p=
.006.Intrusions on LASSI-L List B Cued Recall 1 were also statistically significant
F(1,42) = 25.78, p= .000 with CN individuals making fewer intrusions (M= 3.24) than
those with aMCI (M= 7.07) F(1,42) = 25.78, p= .000. The number of intrusions made
during free recall on the LASSI-L List B Free Recall did not significantly differ between
CN (M=1.67) and aMCI (M=2.20) individuals F(1,42)=.85, p= .36.
Similar results were observed for the LASSI-L measure reflecting frPSI, LASSI-L
List B Cued Recall 2, those were cognitively normal recalled more words when cued (M=
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10.79) than those with aMCI (M= 8.25). This difference was statistically significant
F(1,42)= 13.472, p= .001. The number of intrusions made during List B Cued Recall 2
did not significantly differ between CN (M=2.5) and aMCI (M=3.65) individuals
F(1,42)=3.64, p= .06.
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Table 4-2. ANOVA Summary Table for LASSI-L PSI and frPSI measures
SS

df

MS

F

p

LASSI-L List B Free Recall 1
Between Groups
Within Groups
Total

28.219
202.508
230.727

1
42
43

28.219
4.822

5.853

.020*

LASSI-L List B Cued Recall
1
Between Groups
Within Groups
Total

51.212
255.333
306.545

1
42
43

51.212
6.079

8.424

.006*

LASSI-L List B Cued Recall
2
Between Groups
Within Groups
Total

70.473
219.708
290.182

1
42
43

70.473
5.231

13.472

.001*

LASSI-L List B Free Recall 1
Intrusions
Between Groups
Within Groups
Total

3.103
152.533
155.636

1
42
43

3.103
3.632

.854

.361

LASSI-L List B Cued Recall
1 Intrusions
Between Groups
Within Groups
Total

119.401
194.508
313.909

1 119.401
42
4.631
43

25.782

.000*

14.427
166.550
180.977

1
42
43

3.965

.063

LASSI-L List B Cued Recall
2 Intrusions
Between Groups
Within Groups
Total
Table Notes. *p<.05
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23.201
7.303

Research Question 1c. When cognitive status is grouped by amnestic-MCI and
cognitively normal are there statistically significant differences in African American
older adults cognitive status when examined in terms of LASSI-L measures reflecting
retroactive semantic interference (RSI)?
A one-way analysis of variance was conducted to evaluate the research question
of whether there were statistically significant differences in African American older adult
cognitive status when examined in terms of LASSI-L measures reflecting retroactive
semantic interference (RSI). A criterion for significance of p < .05 was used. On LASSIL measures reflecting retroactive interference (Table 4-3.), results demonstrated higher
scores for CN individuals compared to those with aMCI. For instance, on the LASSI-L
List A Free Recall 2 short delay those who were CN freely recalled more words (M=6.45)
than those with aMCI (M=4.38), F(1,42) = 4.65, p= .037. The number of intrusions made
during LASSI-L List A Free Recall 2 short delay did not significantly differ between CN
(M=2.29) and aMCI (M=3.75) individuals F(1,42)=3.18, p= .08. The number of words
recalled during LASSI-L List A Cued Recall 1 after delay did not significantly differ
between CN (M=7.46) and aMCI (M=6.50) individuals F(1,42)=1.36, p= .25. Similarly,
the number of intrusions made during LASSI-L List A Cued Recall 1 after delay did not
significantly differ between CN (M=3.63) and aMCI (M=4.7) individuals F(1,42)=1.31,
p= .26.
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Table 4-3. ANOVA Summary Table for LASSI-L RSI measures
SS

df

MS

F

p

LASSI-L List A Free Recall 2
Short Delay
Between Groups
Within Groups
Total

28.219
252.758
282.977

1
42
43

28.219
6.066

4.652

.037*

LASSI-L List A Cued Recall
1 After Delay
Between Groups
Within Groups
Total

10.019
308.958
318.977

1
42
43

10.09
7.356

1.362

.250

LASSI-L List A Free Recall 2
Short Delay Intrusions
Between Groups
Within Groups
Total

23.201
306.708
329.909

1
42
43

23.201
7.303

3.177

.082

12.607
405.825
418.432

1
42
43

12.607
9.662

1.305

.260

LASSI-L List A Cued Recall
1 After Delay Intrusions
Between Groups
Within Groups
Total
Table Notes. *p<.05
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Research Question 1d. When cognitive status is grouped by amnestic-MCI and
cognitively normal are there statistically significant differences in African American
older adults cognitive status when examined in terms of LASSI-L measures regarding
delayed recall?
A one-way analysis of variance was conducted to evaluate the research question
of whether there were statistically significant differences in African American older adult
cognitive status when examined in terms of LASSI-L delayed recall (Table 4-4). A
criterion for significance of p < .05 was used. On the LASSI-L Delayed Free Recall, CN
individuals freely recalled more words (M=17.75) than those with aMCI (M=9.70),
F(1,42)= 21.53, p= .000. The number of intrusions made on LASSI-L Delayed Recall did
not significantly differ between CN (M=17.75) and aMCI (M=9.70) individuals
F(1,42)=.77, p=.38.

65

Table 4-4. ANOVA Summary Table for LASSI-L Delayed Recall
SS
LASSI-L Delayed Free
Recall
Between Groups
Within Groups
Total
LASSI-L Delayed Free
Recall Intrusions
Between Groups
Within Groups
Total
Table Notes. *p<.05

706.936
1378.700
2085.636

5.603
304.033
309.636

df

MS

1 706.936
42 32.826
43

1
42
43
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5.603
7.239

F

p

21.536

.000*

.774

.384

Research Question 1e. After controlling for covariates, are there differences on
LASSI-L measures by diagnostic group in African American older adults?
An adjusted analysis of covariance was conducted to control for overall
impairment and literacy level and to determine if after controlling for these covariates, if
there were differences on LASSI-L measures by diagnostic group in African American
older adults. A criterion for significance of p < .05 was used. After controlling for
covariates (Table 4-5), there was only a significant difference on LASSI-L List A Cued
Recall 2 F (1,37) = 11.24, p = .002 and LASSI-L List B Cued Recall 1 Intrusions
F(1,37)= 35.70, p =.000 by diagnostic group indicating more impairment for aMCI on
these LASSI-L measures compared to the cognitively normal group.
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Table 4-5. Test of Between Subjects Effects (ANCOVA)
Type III
SS

df

MS

18.682
17.133
.424
7.044
4.869
154.928
519.000
173.610

3
1
1
1
1
37
41
40

6.227
17.133
.424
7.044
4.869
4.187

1.487
4.092
.101
1.682
1.163

.234
.050
.752
.203
.288

LASSI-L List B Cued
Recall 1 Intrusions
Corrected Model
Intercept
WRAT
MMSE
AA Group
Error
Total
Corrected Total
Intercept

153.704
.856
3.375
.111
137.721
142.735
890.000
296.439

3 51.235
1
.856
1
3.375
1
.111
1 137.721
37
3.858
41
40

13.281
.222
.875
.029
35.700

.000
.640
.356
.866
.000*

LASSI-L List A Cued
Recall 2
Corrected Model
Intercept
WRAT
MMSE
AA Group
Error
Total
Corrected Total
Table Notes. *p<.05

64.801
7.901
1.225
12.835
29.237
96.224
5851.000
161.024

3
1
1
1
1
37
41
40

8.306
3.038
.471
4.935
11.242

.000
.090
.497
.033
.002*

LASSI-L List B Cued
Recall 2 Intrusions
Corrected Model
Intercept
WRAT
MMSE
AA Group
Error
Total
Corrected Total
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21.600
7.901
1.225
12.835
29.237
2.601

F

p

Specific Aim 2: To Determine if Performance on the LASSI-L Serves as a Better
Predator of Diagnostic Group Classification Compared to Other Neuropsychological
Tests in African American Older Adults
Before conducting the step-wise logistic regression included in specific aim 2, the
sample was evaluated to verify that all of the assumptions of logistic regression (i.e.
binary dependent variable, independent observations, multicollinearity, linearity of
independent variables to log odds, adequate sample size) were satisfied and all
assumptions were met.
Research Question 2a. What is the relationship between scores obtained on the
LASSI-L and diagnostic group classification in African American Older Adults?
A step-wise logistic regression was conducted to evaluate the relationship
between scores obtained on the LASSI-L and diagnostic group classification in African
American older adults. A criterion for significance of p < .05 was used. Results (Table 46) demonstrated that both the LASSI-L List B Cued Recall 1 intrusions, b = 1.101, Wald
χ2(1) = 8.04, p = .005, and the LASSI-L Delayed Free Recall b = -.417, Wald χ2(1) =
8.105, p =.004 significantly predicted whether an individual would be diagnosed as CN
or aMCI. A combined overall sensitivity of 91.7%, a specificity of 85.0%, and an overall
classification rate of 88.6% were obtained in distinguishing between individuals who
were CN and those with aMCI. These high classification rates were obtained despite the
fact that the LASSI-L was the only neuropsychological measure that was not employed
as part of the initial diagnostic procedure.
Areas under the receiver operating characteristic curve (ROC) curve on different
LASSI-L variables were also examined (Figure 4-1). Results (Table 4-7) showed that the
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highest area under the curve was obtained for Cued B1 intrusions with an AUC= .870
(SE=.054); p<.001. A cut off of 3 by Youden’s criteria yielded a sensitivity of 83.3% and
a specificity of 77.8%. List B Free Recall intrusions has an AUC of .591 (SE)= (.092)
which did not reach statistical significance (p=.038).
Research Question 2b. What is the relationship between scores on traditional
neuropsychological measures and diagnostic group classification in African American
Older Adults?
Since neuropsychological measures such as the HVLT-R, Category Fluency and
Trails B were part of the initial diagnostic neuropsychological battery, which was
combined with the clinical diagnosis to assign participants to diagnostic groups, using
these same measures, particularly the HVLT-R to predict diagnostic group would result
in potential tautological or circular reasoning. Nonetheless, a step-wise logistic regression
was conducted to evaluate the relationship between scores obtained on traditional
neuropsychological measures and diagnostic group classification in African American
older adults. A criterion for significance of p < .05 was used. Results found that even
when entering variables such as HVLT, Category Fluency, or Trails B, these variables
did not significantly improve the model. Moreover, while HVLT delayed recall played a
large role in determining clinical diagnosis and was individually associated with group
membership, this measure did not surpass individual LASSI-L predictors.
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Table 4-6. Logistic Regression Predicting Diagnostic Group Based on
LASSI-L Measures
B
LASSI-L List B Cued
Recall 1 Intrusions
LASSI-L Delayed
Free Recall
Constant
Table Notes. *p<.05

SE

Wald

df

p

1.101

.388

8.044

1

.005*

Odds
Ratio
3.007

-.417

.147

8.105

1

.004*

.659

.496

1.519

.107

1

.744

1.642

Table 4-7. Area Under the ROC Curve
Area

Std. Asymptomatic
Errora
Sigb

Asymptomatic 95%
Confidence Interval
Lower
Upper Bound
Bound
.411
.770

LASSI-L List B Free .591
.092
.308
Recall Intrusions
LASSI-L List B
.870
.054
.000*
.764
.977
Cued Recall 1
Table Notes. The test result variable(s): LASSI-L List B Free Recall Intrusions,
LASSI-L List B Cued Recall 1 has at least one tie between the positive actual state
group and the negative actual state group. Statistics may be biased
a. Under the nonparametric assumption
b. Null hypothesis: true area = 0.5
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Figure 4-1. Area Under the ROC Curve for LASSI-L variables
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Specific Aim 3: To Explore How Neuropsychological Measures are Related to
Volumetric Reductions in AD Prone Regions in African American Older Adults?
Before conducting the series of Spearman’s rank-order correlation assumption
analyses including examination of scatterplots for monotonic relationships between
variables were conducted and all assumptions were met.
Research Question 3a. Are LASSI-L measures of PSI and frPSI related to MRI
Volumetric Reductions in left hemisphere AD prone regions?
A series of Spearman’s rank-order correlations were run to examine if LASSI-L
measures were related to MRI Volumetric Reductions in left hemisphere hippocampus,
entorhinal cortex, precuneus, temporal lobe (i.e. superior, middle, inferior), parietal (i.e.
superior, inferior), and frontal (i.e. superior, rostral orbital). A criterion for significance of
p < .05 was used. Preliminary results (Table 4-8) demonstrated statistically significant
correlations between the left superior frontal region and LASSI-L B1 Cued Recall
Intrusions rs(27)=-.38, p<.05; left rostral orbital frontal and LASSI-L B1 Cued Recall
Intrusions rs(27)=-.40, p<.05; left rostral orbital frontal and LASSI-L B2 Cued Recall
Intrusions rs(27)=-.44, p<.05. However, after the Benjamini and Hochberg (1995)
correction on the Spearman Rank Order Correlation Coefficients for each LASSI-L
measure (correcting for 10 MRI measures), there were no statistically significant results.

73

Table 8
Table 4-8. Relationship between LASSI and Left Hemisphere Volumes in Alzheimer’s Prone Regions (N=29)
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Variables
1
2
3
4
5
6
7
8
9
10
11
LASSI-L Cued B1 Recall
—
LASSI-L Cued B2 Recall
.00** —
LASSI-L Cued B1 Intrusions .098 .06
—
LASSI-L Cued B2 Intrusions .023* .00** .0** —
Left Hippocampus
.32
.82
.19 .80 —
Left Entorhinal Cortex
.61
.31
.75 .70 .081 —
Left Precuneus
.96
.67
.96 .61 .043* .61 —
Left Superior Temporal
.95
.56
.47 .39 .041* .28 .06
—
Left Middle Temporal
.59
.97
.38 .92 .00** .64 .00** .00** —
Left Inferior Temporal
.64
.76
.10 .28 .047* .03* .03* .045 .00** —
Left Superior Parietal
.68
.73
.25 .51 .00** .15 .00** .089 .00** .00** —
Left Inferior Parietal
.23
.89
.62 .87 .10
.28 .00** .00** .00** .01** .02*
Left Superior Frontal
.80
.96
.04* .54 .001 .02* .00** .017* .00** .00** .00**
Left Rostral Orbital Frontal
.29
.30
.03* .02* .02
.42 .019* .021* .26
.047* .00**
Table Notes. Due to the violation of normality assumptions, non-parametric Spearman Rank Order Correlation
Coefficients were performed with two-tailed significance
*p<.05, **p<.01

12

13

14

—
.00** —
.022* .00** —

Research Question 3b. Are Traditional Neuropsychological Measures related to
MRI Volumetric Reductions in left hemisphere AD prone regions?
A series of Spearman’s rank-order correlations were run to examine if traditional
neuropsychological measures (i.e. HVLT Total, HVLT delay, Trails B, category fluency)
were related to MRI Volumetric Reductions in left hemisphere hippocampus, entorhinal
cortex, precuneus, temporal lobe (i.e. superior, middle, inferior), parietal (i.e. superior,
inferior), and frontal (i.e. superior, rostral orbital). A criterion for significance of p < .05
was used. A criterion for significance of p < .05 was used. The Benjamini and Hochberg
(1995) correction was employed on the Spearman Rank Order Correlation Coefficients
for each traditional measure (correcting for 10 MRI measures), which yielded no
statistically significant results (Table 4-9).
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Table 9
Table 4-9. Relationship between Traditional Measures and Left Hemisphere Volumes in Alzheimer’s Prone Regions (N=29)
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Variables
1
2
3
HVLT-R Total
—
HVLT-R Delay
.00** —
Trails B Total
.00** .00** —
Category Fluency
.01** .028* .00**
Left Hippocampus
.07
.24
.34
Left Entorhinal Cortex
.17
.41
.45
Left Precuneus
.43
.24
.39
Left Superior Temporal
.19
.09
.41
Left Middle Temporal
.44
.12
.42
Left Inferior Temporal
.17
.08
.07
Left Superior Parietal
.36
.36
.31
Left Inferior Parietal
.41
.41
.45
Left Superior Frontal
.20
.20
.40
Left Rostral Orbital Frontal .23
.23
.36
Table Notes. *p<.05 (1 tailed), **p<.01(1 tailed)

4

5

6

7

8

9

10

11

12

13

14

—
.36
.40
.15
.39
.09
.19
.45
.18
.36
.36

—
.082
.008**
.009**
.00**
.00**
.00**
.012*
.001**
.00**

—
.03*
.11
.44
.06
.11
.11
.03*
.17

—
.03*
.00**
.012*
.00**
.00**
.00**
.00**

—
.00**
.059
.018*
.00**
.00**
.00**

—
.00**
.00**
.00**
.00**
.017*

—
.00**
.00**
.00**
.037*

—
.00** —
.00** .00** —
.00** .00** .00** —

Chapter 5: Discussion
Given the paucity of research in the area, the purpose of the current dissertation
study is to extend the body of research on effective early detection of Alzheimer’s disease
(AD) in African Americans. There were three primary aims of the current investigation:
(1) Explore whether there were differences in performance on the LASSI-L between
amnestic-mild cognitively impaired (aMCI) and cognitively normal (CN) African
American older adults, (2) to determine if performance on the LASSI-L serves as a better
predictor of diagnostic group classification compared to other neuropsychological tests in
African American older adults, and (3) Explore how neuropsychological measures are
related to volumetric reductions in AD prone regions in African American older adults.
Primary Outcomes
The first aim of the current study was to explore whether there were differences in
performance on the LASSI-L between aMCI and CN African American older adults.
Specifically, it was predicted that measures sensitive to initial learning and storage,
proactive semantic interference (PSI), failure to recover from proactive semantic
interference (frPSI) and retroactive semantic interference (RSI) would be more impacted
in AA CN versus their aMCI counterparts. Results supported the hypothesis of difference
in performance on LASSI-L measures between diagnosis groups, as those who were
cognitively normal were better able to learn, encode, and store to-be-remembered
information and less susceptible to interference, than those with aMCI. First, with regards
to initial learning and storage of information as measured by List A Free and Cued Recall
1 and 2, those who were cognitively normal were able to recall more words and make
fewer intrusion errors than those with aMCI. These findings suggest that those who were
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CN were better able to learn, encode, and store to-be-remembered information than those
with aMCI. Second, after this initial learning and storage of List A, participants were
asked to learn a second semantically related list of words (List B). The first presentation
of List B assesses for PSI as measured by List B Free and Cued Recall 1. Results found
that cognitively normal individuals remembered more words and made fewer intrusion
errors. These findings indicate that those with aMCI were more susceptible to the effects
of PSI than those who are cognitively normal. Participants were then shown List B again
to provide them with the opportunity to recover from these PSI effects. When examining
participants’ ability or failure to recover from PSI as measured by List B Cued Recall 2,
results found that cognitively normal individuals were able to recall more words than
those with aMCI. These results indicate that individuals with aMCI are more likely to fail
to recover from PSI compared to their cognitively normal counterparts. After the second
presentations of List B, participants were asked to recall words from the original list (List
A) to assess for RSI. Results indicated that cognitively normal individuals were able to
recall more words from the original list during free recall compared to those with aMCI.
This finding suggests that those with aMCI were more susceptible to the effects of RSI.
Delayed recall of both Lists A and B were assessed after 20-minute delay. Results
indicated that cognitively normal individuals were able to recall more words on delayed
recall compared to aMCI. Taken together these results supported the hypothesis that
African Americans diagnosed with aMCI were more impaired in their ability to learn and
remember new information and further, that they were negatively impacted by the effects
of PSI and RSI. Furthermore, these results suggest that those with aMCI failed to recover
from effects of PSI more so than their CN counterparts.
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Given these documented differences on LASSI-L performance occurred within an
older African American sample, additional analyses were conducted in order to account
for known covariates, such as literacy and global cognition. Specifically, several studies
have cited the impact that literacy, as measured by word reading, can have on
neuropsychological test performance. For instance, studies show that African Americans
obtain significantly lower scores than Caucasians on measures of word list learning and
memory, figure memory, abstract reasoning, fluency, and visuospatial skills, but that
these racial differences become nonsignificant when adjusting for literacy (Manly,
Touradji, Tang, & Stern, 2003). Literacy has been found to be the most influential
predictor of cognitive test performance, even after accounting for age, sex, years, of
education, and acculturation level and is thus believed to be a better indicator of cognitive
reserve (Manly, Byrd, & Touradji, 2004). A longitudinal study examining cognitive
decline across racial groups found that older adults with both high and low levels of
literacy decline in immediate and delayed memory over time, but that this decline is more
rapid for low literacy older adults (Manly, Touradji, Tang, & Stern, 2003).
Because of previous research demonstrating the impact that literacy and cognitive
reserve may have on neuropsychological test performance, further analysis was
conducted to control for these effects might have on LASSI-L performance. After
controlling for these variables using the MMSE and WRAT-4 word reading, cognitively
normal and aMCI only differed on their second cued recall of list A and List B cued
recall 1 number of intrusions. These results indicate that those with aMCI exhibit more
impairment in their initial learning and storage of information and suffer from PSI due to
their inability to inhibit responses.
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These results are consistent with previous research on Hispanic and non-Hispanic
individuals which found that those with aMCI had greater difficulty with initial learning
and storage and were more susceptible to PSI compared to those who were cognitively
normal (Crocco et al., 2013; Loewenstein et al., 2016). Given that previous studies have
demonstrated that PSI is one of the strongest predictors of progression from aMCI to
dementia and that cued recall deficits are a more sensitive marker of AD pathology than
free recall, the use of the LASSI-L to identify these deficits may prove valuable in
identifying those individuals who are at risk of further decline (Curiel et al., 2013;
Loewenstein et al., 2016).
Diagnostic Accuracy
The second aim of this study was to determine if performance on the LASSI-L
served as a better predictor of diagnostic group classification compared to other
neuropsychological tests in African American older adults. The obtained findings
indicate that two measures on the LASSI-L (List B Cued Recall 1 intrusions and Delayed
Free Recall) significantly predicted whether an individual would be diagnosed as
cognitively normal or with aMCI. These measures demonstrated a combined overall
sensitivity of 91.7% and a specificity of 85.0%, and a classification rate of 88.6% in
distinguishing between individuals who were cognitively normal and those with aMCI.
Since neuropsychological measures such as the HVLT-R, Category Fluency and
Trails B were part of the initial diagnostic neuropsychological battery, which was
combined with the clinical diagnosis to assign participants to diagnostic groups, using
these same measures, particularly the HVLT-R to predict diagnostic group would result
in potential tautological or circular reasoning. A strength of the LASSI-L was that it was
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completely independent of initial diagnostic formulation. Nonetheless, we conducted
post-hoc analyses entering Trails B, LASSI-L and Category Fluency into logistic
regression models and only LASSI-L List B Cued Recall 1 intrusions and LASSI-L
delayed recall entered into the model. ROC curve analysis demonstrated greatest
sensitivity (83.3%) and specificity (77.8%) using LASSI-L List B Cued Recall 1
intrusions when using a cut off of 3.
Taken together, these results indicate that for African American older adults,
PSI and delayed recall and measured by the LASSI-L are important diagnostic indicators
above and beyond traditional neuropsychological assessments. As such, utilizing the
LASSI-L to assess for PSI and delayed recall may provide high diagnostic accuracy for
this population earlier in the disease state than measures currently utilized. These results
are consistent with previous studies that have demonstrated the LASSI-L’s ability to
differentiate between cognitively normal individuals and those ranging in severity of
impairment in Hispanic and predominately White individuals (Curiel et al., 2013;
Loewenstein et al., 2016). Similarly, these results align with previous studies that
demonstrate that the LASSI-L evidences higher classification rates than those obtained
by other traditional neuropsychological assessment measures among predominately
White individuals (Curiel et al., 2013; Crocco, Curiel, Acevedo, Czaja, & Loewenstein,
2014).
Magnetic Resonance Imaging (MRI)
The third aim of this study was to explore how neuropsychological measures are
related to volumetric reductions in AD prone regions in African American older adults.
After correction for false discovery rates there were no statistically significant results.
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This is inconsistent with previous research where the LASSI-L measures related to PSI
and frPSI were found to uniquely correlate to volumetric reductions on MRI within
medial temporal lobes (e.g. entorhinal cortex) and other AD prone regions (e.g.
precuneus, superior frontal and superior parietal regions) (Loewenstein et al., 2017;
Crocco et al., 2013; Curiel et al., 2013). There are a number of possible explanations for
the lack of significant MRI findings. First, despite including the entire sample (both CN
and aMCI), which is consistent with prior studies, the sample size available for MRI
scans was modest and did not provide enough statistical power to yield significant results.
Secondly, given the population of interest, community based African Americans; the
participants may have had underlying conditions other than AD to a greater extent than
the samples utilized in previous studies (i.e. Hispanic and predominately White
individuals) (Brooks & Loewenstein, 2010). To this point, many participants evidenced
cardiovascular risk factors such as hypertension, diabetes, hypercholesterolemia, and
history of stroke (Table 5-1). These risk factors, as well as the high rates of past drug use
typically seen in African American Baby Boomers (Pope, Wallhagen, & Davis, 2010)
may indicate that the memory loss observed in this sample may more accurately be
classified as mixed etiology. As such, future studies should seek to recruit a larger sample
without major health conditions known to impact cognition. In addition, future studies
may benefit from the use of PET amyloid scans and/or tau imaging to determine if other
biomarker correlates of AD are be present.
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Table 5-1. Cardiovascular Risk Factors.4
aMCI (n=16)
Hypertension
Diabetes
Hypercholestrolemia
Stroke

4

68.8%
23.5%
31.3%
11.8%

Cognitively
Normal (21)
52.4%
19.0%
23.8%
4.8%

Note. No cases had reported history of CFH or heart attack
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X2 Yate’s
Correction
.45
.00
.02
.04

p
.51
1.00
.80
.85

Strengths
The current dissertation study has several strengths, including those related to
design characteristics. Specifically the current study utilized a detailed, well-established
and standardized criteria for the evaluation and diagnosis of both CN and aMCI patients,
as well as, expert readings of volumetric magnetic resonance imaging data for
participants, and the analyses included false discovery rates to control for false errors
(Benjamini & Hochberg, 1995). Additionally, this dissertation study adds to the present
literature base by examining LASSI-L. performance in African Americans, which are an
underserved and underrepresented population in clinical research. This is significant as
prevalence and incidence rates of dementia diagnoses across racial and ethnic groups
have found that the rates of dementia among African Americans far outnumber that of
other racial and ethnic groups (Mehta & Yeo, 2017). Furthermore, the current study is
one of the first to determine the extent to which proactive, retroactive, and failure to
recover from proactive semantic interference on a novel cognitive stress test could
differentiate between aMCI and cognitively normal African American older adults.
Limitations
While the current study had several strengths, a number of limitations are worth
noting. First, one important limitation of the current study is that of the forty-four total
participants (24 of these participants were diagnosed as cognitively normal and 20 were
diagnosed as having mild cognitive impairment) only 29 of these individuals underwent
MRI scans and, as such, normal and MCI participants were combined. Additional
participants would have increased the power of statistical tests, allowed for additional
covariates such as health factors to be examined, and thus provided higher external

84

validity. However, recruitment of African American participants is complicated by a
number of factors including mistrust of health care providers and researchers, as well as
personal and historic discrimination (Mahoney et al., 2005). In fact, many African
Americans report being unwilling to participate in research due to historic research
instances such as the Tuskegee Study of Untreated Syphilis (Green et al., 1997). Personal
discrimination, particularly in the Southern United States where this study was
conducted, may also have added to this sense of mistrust in potential participants
(Mahoney et al., 2005). Additionally, this study involved the recruitment of participants
belonging to the Baby Boom cohort (i.e. those born between mid-1946 and mid-1964)
who have been found to be more pessimistic regarding individuals in lower social status
or those viewed as less fortunate (Riggs & Turner, 2000; Hogan, Perez, & Bell, 2008).
Because this study consists largely of African American participants who were recruited
from local churches, the sample is likely skewed and represents unique variance not
accounted for by this study.
Second, despite comprehensive screening with the NPI to exclude participants
meeting full criteria for a Major Mood Disorder from the study, there is a possibility that
some participants may have experienced a sub-syndromal mood disorder that could have
affected cognitive performance. We believe that this is unlikely as previous research has
shown no evidence between mild mood symptoms and performance on the LASSI-L
(Crocco et al., 2018) however future research is needed in order to confirm these
findings.
Third, the fact that the LASSI-L’s diagnostic accuracy was compared to memory
measures used as part of the diagnostic process creates a degree of circularity. Even
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though the LASSI-L still compared favorably, future studies would benefit from the
comparison of the LASSI-L and neuropsychological measures, which were not used in
the diagnostic process.
Finally, it is possible that this community dwelling AA population did not have
underlying AD pathology but instead were experiencing cognitive symptoms due to other
etiologies. As such, future research should seek to recruit participants with fewer
cardiovascular risk factors.
Future Directions
Future studies should continue to investigate the performance of African
Americans, with varying severity of impairment, on the LASSI-L. Recruiting a larger
sample of participants would help future investigators better evaluate the LASSI-L’s
diagnostic features and accuracy among this population. Future studies should attempt to
recruit a more diverse sample (e.g. different geographic regions, recruitment settings).
Due to high levels of health risk factors observed in this sample, future studies should
also attempt to recruit participants with family histories of AD, identified with amyloid
and tau pathology by PET scan imaging, as well as, focus on individuals with both high
and low levels of cardiovascular risk factors so as to better isolate a purely AD pathology.
Because literacy has been linked to neuropsychological test performance and rates of
cognitive decline over time, future studies should account for literacy levels to examine
the effects it may have on performance, particularly in minority populations. Finally,
future studies should include the comparison of the LASSI-L’s diagnostic accuracy to the
diagnostic accuracy rates of other independent neuropsychological measures for African
Americans with varying severity of cognitive impairment.
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Conclusions
In conclusion, the majority of the results of this dissertation are consistent with
the prior literature in that there are differences in performance on the LASSI-L between
diagnostic groups and the LASSI-L was able to differentiate between those diagnosed
with aMCI and those who are cognitively normal with high-observed specificity and
sensitivity. Specifically, the current dissertation found that those with aMCI have greater
difficulty with initial learning and storage of information and are more susceptible to PSI
and some aspects of frPSI and RSI compared to those who were cognitively normal.
However, after controlling for global cognition and literacy, only aspects of PSI and RSI
remained predictive. Furthermore, inconsistent with the prior literature, the current study
did not find LASSI-L measures related to volumetric reductions in AD prone brain
regions. This inconsistency may be due to a modest sample size and/or, given the high
rates of cardiovascular risk factors within the sample, the observed memory loss may
have been caused by other etiologies. Despite this inconsistency, demographic trends and
projected prevalence rates of AD within African Americans (Celsis, 2000; Sherwin,
2000), coupled with the fact that emerging dementias therapies are more effective in the
earlier stages, establish an increasing need for early detection of AD in susceptible
populations (Loewenstein, Curiel, Duara, & Buschke, 2017). As such, cognitive stress
tests such as the Loewenstein-Acevedo Scale of Semantic Interference and Learning
(LASSI-L), can provide quick, accurate, and inexpensive diagnostic classification across
impairment severity (Loewenstein, Curiel, Duara, & Buschke, 2017) and, as shown in
this dissertation, across racial groups. Overall, the current study, in line with previous
research, suggests that the LASSI-L holds promise as a diagnostic tool that can be used
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by clinicians for identifying mild cognitive impairment among African American older
adults.
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Major or Mild Neurocognitive Disorder Due to Alzheimer’s Disease
A. The criteria are met for major or mild neurocognitive disorder.
B. There is insidious onset and gradual progression of impairment in one or more
cognitive domains (for major neurocognitive disorder, at least two domains must
be impaired).
C. Criteria are met for either probable or possible Alzheimer’s disease as follows:
For major neurocognitive disorder:
Probable Alzheimer’s disease is diagnosed if either of the following is
present; otherwise, possible Alzheimer’s disease should be diagnosed.
(1) Evidence of a causative Alzheimer’s disease genetic mutation from family
history or genetic testing.
(2) All three of the following are present:
a) Clear evidence of decline in memory and learning and at least one other
cognitive domain (based on detailed history or serial neuropsychological
testing).
b) Steadily progressive, gradual decline in cognition, without extended
plateaus.
c) No evidence of mixed etiology (i.e., absence of other neurodegenerative or
cerebrovascular disease, or another neurological, mental, or systemic
disease or condition likely contributing to cognitive decline).
For mild neurocognitive disorder:
Probable Alzheimer’s disease is diagnosed if there is evidence of a causative
Alzheimer’s disease genetic mutation from either genetic testing or family
history.
Possible Alzheimer’s disease is diagnosed if there is no evidence of a
causative Alzheimer’s disease genetic mutation from either genetic testing or
family history, and all three of the following are present:
1) Clear evidence of decline in memory and learning.
2) Steadily progressive, gradual decline in cognition, without extended
plateaus.
3) No evidence of mixed etiology (i.e., absence of other neurodegenerative or
cerebrovascular disease, or another neurological or systemic disease or
condition likely contributing to cognitive decline).
D. The disturbance is not better explained by cerebrovascular disease, another
neurodegenerative disease, the effects of a substance, or another mental,
neurological, or systemic disorder.
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental
disorders (5th ed.). Arlington, VA: American Psychological Association.
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F00

Dementia in Alzheimer’s disease

The following features are essential for a definite diagnosis:
A. Presence of a dementia as described above.
B. Insidious onset with slow deterioration. While the onset usually seems difficult to
pinpoint in time, realization by others that the defects exist may come suddenly.
An apparent plateau may occur in the progression.
C. Absence of clinical evidence, or findings from special investigations, to suggest
that the mental state may be due to other systemic or brain disease which can
induce a dementia (e.g. hypothyroidism, hypercalcaemia, vitamin B12 deficiency,
niacin deficiency, neurosyphilis, normal pressure hydrocephalus, or subdural
hematoma).
D. Absence of a sudden, apoplectic onset, or of neurological signs of focal damage
such as hemiparesis, sensory loss, visual field defects, and incoordination
occurring early in the illness (although these phenomena may be superimposed
later).
In a certain proportion of cases, the features of Alzheimer's disease and vascular
dementia may both be present. In such cases, double diagnosis (and coding)
should be made. When the vascular dementia precedes the Alzheimer's disease, it
may be impossible to diagnose the latter on clinical grounds.
Includes: primary degenerative dementia of the Alzheimer's type
Differential diagnosis. Consider: a depressive disorder (F30-F39); delirium
(F05.-); organic amnesic syndrome (F04); other primary dementias, such as in
Pick's, Creutzfeldt-Jakob or Huntington's disease (F02.-); secondary dementias
associated with a variety of physical diseases, toxic states, etc. (F02.8); mild,
moderate or severe mental retardation (F70-F72).
Dementia in Alzheimer's disease may coexist with vascular dementia (to be coded
F00.2), as when cerebrovascular episodes (multi-infarct phenomena) are
superimposed on a clinical picture and history suggesting Alzheimer's disease.
Such episodes may result in sudden exacerbations of the manifestations of
dementia. According to postmortem findings, both types may coexist in as many
as 10-15% of all dementia cases.
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F00.0 Dementia in Alzheimer's disease with early onset
Dementia in Alzheimer's disease beginning before the age of 65. There is
relatively rapid deterioration, with marked multiple disorders of the higher
cortical functions. Aphasia, agraphia, alexia, and apraxia occur relatively early in
the course of the dementia in most cases.
Diagnostic Criteria: As for dementia, described above, with onset before the age
of 65 years, and usually with rapid progression of symptoms. Family history of
Alzheimer's disease is a contributory but not necessary factor for the diagnosis, as
is a family history of Down's syndrome or of lymphoma.
Includes: Alzheimer's disease, type 2 presenile dementia, Alzheimer's type
F00.1 Dementia in Alzheimer's disease with late onset
Dementia in Alzheimer's disease where the clinically observable onset is after the
age of 65 years and usually in the late 70s or thereafter, with a slow progression,
and usually with memory impairment as the principal feature.
Diagnostic guidelines: As for dementia, described above, with attention to the
presence or absence of features differentiating the disorder from the early-onset
subtype (F00.0).
Includes: Alzheimer's disease, type 1 senile dementia, Alzheimer's type
World Health Organization. (1993). The ICD-10 classification of mental and behavioural
disorders. Geneva, Switzerland: Author.
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National Institute of Neurological and Communicative Disorders and Stroke (Nincds) of
The United States and The Alzheimer’s Disease and Related Disorders
Association (Adrda) Diagnosis of Alzheimer's Disease Critera
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I. The criteria for the clinical diagnosis of PROBABLE Alzheimer’s disease include:
— dementia established by clinical examination and documented by the MiniMental Test, Blessed Dementia Scale, or some similar examination, and confirmed
by neuropsychological tests;
— deficits in two or more areas of cognition;
— progressive worsening of memory and other cognitive functions;
— no disturbance of consciousness;
— onset between ages 40 and 90, most often after age 65; and
— absence of systemic disorders or other brain diseases that in and of themselves
could account for the progressive deficits in memory and cognition.
II. The diagnosis of PROBABLE Alzheimer’s disease is supported by:
— progressive deterioration of specific cognitive functions such as language
(aphasia), motor skills (apraxia), and perception (agnosia);
— impaired of activities of daily living and altered patterns of behavior;
— family history of similar disorders, particularly if confirmed
neuropathologically; and
— laboratory result of:
— normal lumbar puncture as evaluated by standard techniques,
— normal pattern or nonspecific changes in EEG, such as increased slow-wave
activity, and
— evidence of cerebral atrophy on CT with progression documented by serial
observation.
III. Other clinical features consistent with the diagnosis of PROBABLE Alzheimer’s
disease, after exclusion of causes of dementia other than Alzheimer’s disease, include:
— plateaus in the course of progression of the illness;
— associated symptoms of depression, insomnia, incontinence, delusions, illusions,
hallucinations, catastrophic verbal, emotional, or physical outbursts, sexual
disorders, and weight loss;
— other neurologic abnormalities in some patients, especially with more advanced
disease and including motor signs such as increased muscle tone, myoclonus, or
gait disorder;
— seizures in advanced disease; and
— CT normal for age.
IV. Features that make a diagnosis of PROBABLE Alzheimer’s disease uncertain or
unlikely include:
— sudden, apoplectic onset;
— focal neurologic findings such as hemiparesis, sensory loss, visual field deficits,
and incoordination early in the course of the illness; and
— seizures or gait disturbances at the onset or very early in the course of the
illness.
V. Clinical diagnosis of POSSIBLE Alzheimer’s disease:
— may be made on the basis of the dementia syndrome, in the absence of other
neurologic, psychiatric, or systemic disorders sufficient to cause dementia, and in
the presence of variations in the onset, in the presentation, or in the clinical course;
— may be made in the presence of a second systemic or brain disorder sufficient to
produce dementia, which is not considered to be the cause of the dementia; and
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— should be used in research studies when a single, gradually progressive severe
cognitive deficit is identified in the absence of other identifiable cause.
VI. Criteria for diagnosis of DEFINITE Alzheimer’s disease are:
— the clinical criteria for probable Alzheimer’s disease; and
— histopathologic evidence obtained from a biopsy or autopsy.
VII. Classification of Alzheimer’s disease for research purposes should specify features
that may differentiate subtypes of the disorder, such as:
— familial occurrence;
— onset before age of 65;
— presence of trisomy-21; and
— coexistence of other relevant conditions such as Parkinson’s disease.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, M. E.
(1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work
group* under the auspices of department of health and human services task force on
Alzheimer’s disease. Neurology, 34(7), 939-944. doi:10.1212/WNL.37.7.939
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Loewenstein-Acevedo Scales of Semantic Interference and Learning (LASSI-L)
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